


Synthesis of Polyhydroxylated Quinolizidine and Indolizidine Scaffolds from Sugar-Derived Lactams via a One-Pot Reduction/Mannich/Michael Sequence

Piotr Szcześniak, Sebastian Stecko,* Elżbieta Maziarz, Olga Staszewska-Krajewska, and Bartłomiej Furman*

Institute of Organic Chemistry, Polish Academy of Sciences Kasprzaka 44/52, 01-224 Warsaw, Poland



Supporting Information



ABSTRACT: A direct approach to the synthesis of indolizidine and quinolizidine scaffolds of iminosugars is described. The presented strategy is based on a one-pot sugar lactam reduction with Schwartz's reagent followed by a diastereoselective Mannich/Michael tandem reaction of the resulting sugar imine with Danishefsky's diene. The stereochemical course of the investigated reaction has been explained in detail. The obtained bicyclic products are attractive building blocks for the synthesis of various naturally occurring polyhydroxylated alkaloids and their derivatives.

INTRODUCTION

The synthesis and biological properties of polyhydroxylated indolizidine alkaloids (iminosugars) such as castanospermine, swainsonine, lentiginosine, and their synthetic quinolizidine analogues (1–4) have received considerable interest in recent years.¹ Due to their structural resemblance to sugars, iminosugars are recognized by glycosidases, the enzymes responsible for formation or hydrolysis of glycosyl bonds in carbohydrates and glycoconjugates, which may result in inhibition of their activity.^{1b,c} Thanks to this feature, iminosugars have demonstrated a range of biological activity (e.g., antiviral, anti-HIV, anticancer, antifeedant, immunoregulatory activity, and more) that target a wide choice of diseases.¹ The approval of Glyset and Zavesca for the treatment of complications associated with type II diabetes and for Gaucher's disease, respectively, within the past decade, is a testament to their importance as medicines for unmet medical needs.¹ Clearly, the field of iminosugars is a fertile area for research on both chemical and biological frontiers.



Several strategies for the synthesis of bicyclic iminosugar systems based on either chiral pool or enantio- and diastereoselective approaches have been developed.² The first group of methods employs mainly hydroxyacids and carbohydrates as starting materials.^{1b,c,3,4} The last two approaches involve linear and stepwise formation of a piperidine or pyrrolidine ring followed by intramolecular cyclization leading to a bicyclic pyrrolizidine, indolizidine, or quinolizidine scaffold.^{5–7} The most explored strategies rely on 1,3-dipolar cycloaddition of chiral nitrones with olefins,^{8–12} developed by Tufariello¹³ and extended by Brandi,¹⁴ Vasella,¹⁵ Vogel,¹⁶ and our group.¹⁷


The asymmetric Mannich/Michael tandem reaction (formal aza-Diels–Alder reaction), which has long proven to be an invaluable aid in enabling access to highly functionalized six-membered nitrogen-containing heterocycles,¹⁸ can be envisioned as an alternative way. In the past, we demonstrated that dihydropyridones, generated in situ via a Mannich/Michael sequence of acyclic imines with electron-rich Danishefsky-type dienes,¹⁹ can be used as building blocks for the construction of indolizidine and quinolizidine scaffolds through either rhodium-catalyzed intramolecular conjugate addition of vinylstannanes²⁰ or fluoride ion induced intramolecular conjugate addition of propargylsilanes.²¹

Although the studies on the acyclic imine-involved Mannich/Michael reactions are advanced,^{18b–d,22–26} the examples of analogous reactions that employ nonactivated cyclic imines are rare.^{27–31} Despite the fact that the Mannich/Michael process

Received: September 18, 2014

Published: October 13, 2014

Scheme 1



involving cyclic imines provides a direct entry to the indolizidine or quinolizidine scaffold, its potential as a tool of synthetic organic chemistry remains unexploited. Such an approach would be even more attractive if sugar-derived imines were to be applied, since the resulting products, bicyclic enamines, can serve as direct precursors of indolizidine or quinolizidine iminosugars (Scheme 1). Herein, we wish to report the use of optically active, sugar-derived imines as coupling partners to achieve a highly diastereoselective cyclocondensation as a route to various of bicyclic iminosugars.

RESULTS AND DISCUSSION

We started our investigation with the preparation of various sugar-derived imines. The standard way of preparing simple cyclic imines is *N*-chlorination of cyclic amines followed by elimination.³² However, this approach is less viable in the case of sugar-derived imines, since it is difficult to control the regioselectivity of elimination of the corresponding *N*-chloroamines, which leads to the formation of inseparable mixtures of isomeric imines. Additionally, in many cases the synthesis of initial amines is not a straightforward task. Therefore, we considered a more facile approach to the preparation of imines.

On the basis of our previous experience,³³ we focused our attention on sugar-derived nitrones as imine precursors. For this purpose the pentose-derived nitrones **5a,b**^{34–36} were prepared according to literature protocols. The additional two nitrones **5c**^{14b} and **5d**,^{14d} derived from chiral hydroxyacids, were also prepared. These compounds were subjected to phosphine-mediated deoxygenation, leading to corresponding imines **6a–d** in good yields (Table 1).³⁷ All of the imines are rather unstable molecules; however, careful chromatography on Florisil allowed us to obtain them in pure form.

Imines **6a–d** were submitted to a Yb(OTf)₃-catalyzed addition/cyclization tandem reaction with Danishefsky's diene (DD) according to our previous reports.^{19–21} The corresponding bicyclic enamines **7a–d** were obtained in moderate yields and with good to high diastereoselectivity (Table 2).

Since imines have limited stability, we wondered if both steps, deoxygenation and cyclocondensation, could be performed in a one-pot manner without isolation of the intermediate imine. However, all attempts to perform the above sequence in a one-pot manner failed. No formation of the desired indolizidine product was noticed. Moreover, although the above approach worked well for five-membered imines, it was not suitable for the formation of quinolizidines from six-membered imines. The main problem was the limited availability of six-membered sugar-derived nitrones; these compounds are more difficult to prepare and are less stable than their five-membered congeners.³⁸ In addition, the formation of the six-membered imines was another challenging; despite many attempts, these compounds were formed in poor yields and were highly unstable. Therefore, we decided to revise our synthetic approach and find another source of cyclic imines which would provide a straightforward and general route to polyhydroxylated indolizidines and quinolizidines.

Table 1. Synthesis of Imines via Phosphine-Mediated Deoxygenation of Nitrones^a


Entry	Nitron	Imine	Yield ^b [%]
1			83
2			67
3			85
4			69









^aReaction conditions: Bu₃P (2.0 equiv), THF, 75 °C, 24–48 h.

^bIsolated yield.

Very recently, we have demonstrated that sugar-derived imines can be easily generated by the reduction of carbohydrate-derived lactams with Schwartz's reagent.^{39–41} The main advantage of the developed method relies on the fact that the generated imine can be further functionalized by direct treatment with a nucleophile in a "one-pot" manner. As we demonstrated,³⁹ this one-pot reduction/nucleophilic addition is an attractive way to synthesize monocyclic iminosugars, particularly in cases when other methods, for instance those based on nucleophilic addition to nitrones, cannot be applied. Encouraged by those results, we decided to apply the same approach in the current studies. Another benefit of such an approach would be the availability and stability of sugar-derived lactams. Since they are accessible from carbohydrate sources, either five- or six-membered lactams can be prepared. A typical preparation of sugar lactams is exemplified in Scheme 2.^{39,42} *gluco*-Lactam **8** was chosen as a model starting material for our further studies.

Lactam **8** was treated with Cp₂Zr(H)Cl (1.6 equiv) in THF to afford imine **9**, as presented in Scheme 3.³⁹ The progress of the reaction can be easily followed: the transition of the reaction mixture from an initially white suspension into a clear solution indicates the end of the reduction (ca. 30 min). The

Table 2. Synthesis of Indolizidines and Quinolizidines via Mannich/Michael Reaction of Cyclic Imines with DD^a


Entry	Substrate	Product (major isomer)	Yield ^b [%]	<i>d.r.</i> ^c [%]
1			68	95:5
2			55	86:14
3			69	86:14
4			64	92:8


^aReaction conditions: diene (2 equiv), Lewis acid (10 mol%), CH₂Cl₂ at -25 °C for 30 min then 3 h at room temperature. ^bIsolated yield. ^cDetermined by ¹H NMR or HPLC of the crude reaction mixture.

resulting imine was directly subjected to the cyclocondensation reaction. Thus, the diene (2 equiv) and Yb(OTf)₃ (10 mol%) were added at -25 °C, and the reaction mixture was warmed to room temperature. The desired bicyclic enaminones **10** and **9a-*epi*-10** were obtained in 80% yield and with a high level of stereoselectivity (*d.e.* 94.6%) (Table 3, entry 1). The absolute configuration of the major product **10** was confirmed by X-ray analysis of its hydrogenated derivative **11** (Scheme 4).

Next, the influence of various Lewis acids on the yield and diastereoselectivity of the investigated process was evaluated. The replacement of Yb(OTf)₃ by scandium or lanthanum triflates resulted in a decrease of the overall yield and only had a slight influence on the reaction stereoselectivity (Table 3, entries 4 and 5 vs entry 1). The reduction of the catalyst loading resulted only in lowering of the reaction yield (Table 3, entries 2 and 3). BF₃·Et₂O displayed only moderate catalytic activity and provided the desired products **10** and **9a-*epi*-10** in 66% yield. The stereoselectivity remained very high. Among the

various silyl triflates tested, TBSOTf provided the highest yield for the model reaction (Table 3, entry 8). The catalytic efficiency of TBSOTf was comparable with the results obtained for the Yb(OTf)₃-catalyzed process (Table 3, entry 8 vs entry 1). Thus, 10 mol% loading of the Lewis acid was optimal. To confirm that the addition step is catalyzed by an external Lewis acid and not the zirconium salts present in the reaction mixture, a blank experiment was performed. In the absence of a Lewis acid (e.g., Yb(OTf)₃) no formation of the desired product was observed (Table 3, entry 12).


With the optimal reaction conditions (10 mol% of Yb(OTf)₃ in THF) in hand, we set out to examine sugar-derived lactams **12–17** as well as simple enantiopure alkoxy-substituted lactams **18–22** to establish the reaction generality.



Sugar lactams **12–17** were prepared from commercially available carbohydrates following the general route presented in Scheme 2.^{39,42,43} In the same manner, lactam **19** was prepared starting from D-erythrone. Its diastereomer, lactam **18**, was obtained from tartaric acid derived imide **23**,⁴⁴ via the reaction sequence depicted in Scheme 5. With L-malic acid as the starting material, regioisomeric lactams **20** and **21** were prepared (Scheme 6).⁴⁵ Finally, lactam **22** was prepared from ethyl L-pyroglytamate following a literature procedure.⁴⁵



With various chiral cyclic lactones in hand, we subjected them to the one-pot reduction/Mannich/Michael tandem reaction. As shown in Table 4, all investigated examples of the one-pot reduction/aza-Mannich/Michael tandem reaction proceeded with good yields and good to high diastereoselectivity to provide bicyclic enaminones **10** and **32–41** as the major isomers. The absolute configuration at the newly formed bridgehead carbon atom was assigned on the basis of an analysis of coupling constants and NOE experiments.

Finally, we decided to ascertain if the size of the silyl group in the diene could influence the stereoselectivity of the process. As

Scheme 2. General Route to Sugar-Derived Lactams **8 and **12–17**^a**

^aReagents and conditions: (a) (COCl)₂, DMSO, Et₃N, CH₂Cl₂, -78 °C; (b) (i) NH₃(l), Et₂O, -78 °C, (ii) SO₃·Py, DMSO; (c) Et₃SiH, BF₃·Et₂O, MeCN, CH₂Cl₂.

Scheme 3

Table 3. Lewis Acid Effect on the Formation of 10 via Lactam Reduction/Diene Addition Sequence^a

entry	Lewis acid (amt (mol%))	yield (%) ^b	d.e. (%) ^c
1	Yb(OTf) ₃ (10)	80	95.8
2	Yb(OTf) ₃ (5)	51	94.4
3	Yb(OTf) ₃ (1)	35	94.7
4	Sc(OTf) ₃ (10)	55	96.4
5	La(OTf) ₃ (10)	77	92.2
6	BF ₃ ·Et ₂ O (10)	66	96.4
7	TMSOTf (10)	68	94.2
8	TBSOTf (10)	75	95.8
9	TBSOTf (5)	58	94.2
10	TBSOTf (2)	26	93.0
11	TIPSOTf (10)	53	96.0
12	none	0	

^aReaction conditions: (step 1) Cp₂Zr(H)Cl (1.6 equiv) in THF at -25 °C for 30 min; (step 2) diene (2 equiv), Lewis acid (10 mol%) at -20 °C for 30 min and then 3 h at room temperature. ^bIsolated yield (overall after two steps). ^cDetermined by HPLC of the crude reaction mixture.


shown in Table 5, replacement of Danishefsky's diene by its analogue with a TBS group let us increase the diastereoselectivity of the reaction with lactam **14** derived imine. In the case of lactam **18** the use of a diene with the bulkier silyl group resulted in a slight decrease of stereoselectivity and an increase in the overall reaction yield.


Although the method described above enables the efficient and highly stereoselective formation of polyhydroxylated indolizidinones and quinolizidinones, we encountered some problems during the isolation and purification of the desired products. Since the products, formed through the described

sequential reduction/Mannich/Michael reaction, may differ only at a single bridgehead position, the separation of isomeric products was not a trivial task. In some cases the separation of products by classic column chromatography was not effective; even FCC and preparative HPLC did not give satisfying results (although the results of analytical HPLC analysis were promising). Crystallization techniques were also ineffective, since most of the obtained products were oils and all attempts to force them to crystallize failed. An alternative approach involving derivatization of the obtained products by a complete or partial exchange of O-Bn protecting groups for different groups, such as Bz, PMB, TBS, THP, etc., also did not give satisfying results in comparison to the effort expended. The increase of the selectivity of the process to minimize the formation of the minor isomer, e.g. by modifying the structure of the starting materials, could present an alternate solution to this problem. Unfortunately, the comparison of our data with those of closely related works by Shao and Yang³¹ (for example, for the synthesis of **37**) indicates that the replacement of the benzyl protecting group with the bulkier O-TBS group gives only a slight increase in the selectivity of the process. In addition, as demonstrated in Tables 3 and 5, the use of a bulkier Lewis acid, such as TBSOTf, or a modified diene also provides only slight changes in the level of diastereoselectivity of the investigated process. So far, the isolation of products and increase of diastereoselectivity of the addition step are still an open question, and our current efforts are focused on developing a suitable solution.


Stereochemical Proofs and Analysis of the Stereochemistry of the Investigated Reduction/Mannich/Michael Sequence. The formation of bicyclic enaminones is a stepwise process involving a Mannich reaction followed by Michael addition. Therefore, its stereochemical outcome is governed by the course of the nucleophilic addition to the imine group. However, such analysis is not as straightforward as it seems at first glance and both steric and stereoelectronic effects must be taken into consideration to permit the correct prediction and rationalization of its stereochemical course. For this reason in our studies we employed the stereochemical

Scheme 4



Scheme 5. Synthesis of Lactam 18^a

^aReagents and conditions: (a) NaBH₄, MeOH/CH₂Cl₂, -78 °C to room temperature, 24 h, 89%; (b) Ac₂O, Et₃N, CH₂Cl₂, 24 h, 69%; (c) BF₃·Et₂O, Et₃SiH, CH₂Cl₂, -78 to 0 °C, 3 h, 95%; (d) CAN, MeCN/H₂O, 0 °C, 6 h, 73%.

Scheme 6. Synthesis of Lactams 20 and 21^a

^aReagents and conditions: (a) BnBr, Ag₂O, Et₂O, room temperature, 24 h, 93%; (b) LiEt₃BH, Ac₂O, CH₂Cl₂, -78 °C to room temperature, 24 h, 91%; (c) BF₃·Et₂O, Et₃SiH, CH₂Cl₂, -78 °C to room temperature, 24 h, 87% (30:31 ratio 94:6); (d) CAN, MeCN/H₂O, 0 °C to room temperature, 24 h, 86%; (e) CAN, MeCN/H₂O, 0 °C to room temperature, 24 h, 76%.

models proposed by Woerpel and co-workers,⁴⁶ which describe the stereochemical course of C-allylation reactions of furanosyl and pyranosyl oxycarbenium ions. Due to several parallels between both types of reactions, we assumed that it can be applied as a working model for our process.

Woerpel's rationalization is based on the conformational preferences of the intermediate oxocarbenium ions and argues that the orientation preferences of the ring substituents dictate the relative stabilities of the possible oxocarbenium ion conformers and govern the approach of allyl species to oxycarbenium ions.

Stereochemistry of Reactions Involving Five-Membered Imines. Woerpel's model assumes that, for furanosyl oxycarbenium ions (with an envelope conformation), alkoxy substituents at C-2 and C-3 preferentially take the equatorial and axial positions, respectively (Scheme 7).^{46e} The C-4 alkyl substituent does not have a strong preference for either orientation but can play an important role in combination with the other ring substituents through mutual steric interactions. Nucleophiles would then approach the intermediate envelope oxocarbenium ions preferentially from the "inside" (the side of the envelope syn to the carbon atom which lies out of the envelope plane; Scheme 7) to avoid developing eclipsing interactions with the neighboring ring substituent.^{46e}

According to the above assumptions, the addition of DD to the lactam 20 derived imine 42 should result in the formation of the 2,8a-cis isomer as the major product, as shown in Scheme 8. Indeed, NOE experiments confirmed the relative cis configuration of protons at the C-2 and C-8a positions for compound 39. The same cis selectivity was also observed by Seebach⁴⁷ during the allylation of five-membered 3-silyloximinium ions.

For 4,5-disubstituted imines 6b and 43 the observed outcome of addition also corresponded well with Woerpel's model, and compounds 7b and 36 with a 2,8a-cis relative configuration were obtained as the major products (Scheme 9). This result also confirmed that the electronic nature of the substituent at C-4 exerts a powerful effect upon selectivity. At the same time, it confirmed a small influence of the CH₂OBn substituent at the C-5 position; regardless of the configuration at the C-5 position the formation of the bridgehead stereocenter was influenced predominantly by the C-4 center of the imine.

As indicated in Table 4, the addition of DD to the 3,4-disubstituted imines *threo*-44 and *erythro*-45 (Schemes 9 and 10) provided compounds 37 and 38, respectively, as the major products. In both cases the 1,8a-trans relative configuration was assigned.

As disclosed in Scheme 10, the course of the addition to imine 44 can be easily explained Woerpel's stereoelectronic model (via the ⁴E conformer). The same course of addition of DD to imine 44 was observed by Yang and Shao.³¹

On the other hand, the formation of compound 38 as the major product is in opposition to the outcome of the allylation of the corresponding furanosyl oxycarbenium ion,^{46e} which provides the cis isomer, and suggests that the addition to imine 45 is probably governed by steric effects. This effect may be associated with steric repulsion of the alkoxy substituent located at the C-3 position that should favor a syn approach of the nucleophile through the E₄ conformer (Scheme 11).

Another explanation is also possible. Woerpel's stereochemical model has been based on the results of addition of allyltrimethylsilane to various five- and six-membered oxycarbenium ions and does not take into consideration the

Table 4. Synthesis of Indolizidines and Quinolizidines via One-Pot Reduction/Mannich/Michael Tandem Reaction Starting from Lactams 10 and 12–22^a

Entry	Substrate	Product (major isomer)	Yield ^b [%]	d.r. ^c [%]	Entry	Substrate	Product (major isomer)	Yield ^b [%]	d.r. ^c [%]
1			80	98:2	7			61	87:13
2			73	94:6	8			55	90:10
3			81	90:10	9			63	86:14
4			67	88:12	10			63	80:20
5			62	96:4	11			51	85:15
6			75	96:4	12			55	82:18 ^d


^aReaction conditions: (step 1) Cp₂Zr(H)Cl (1.6 equiv) in THF for 30 min; (step 2) diene (2 equiv), Lewis acid (10 mol%) at –20 °C for 30 min and then 3 h at room temperature. ^bIsolated yield (overall after two steps). ^cDetermined by ¹H NMR or/and HPLC of the crude reaction mixture. ^dAbsolute configuration at the bridgehead position of the major product could not be unambiguously assigned.

influence of the nucleophile on the course of the addition. Surely, Danishefsky's diene is a sterically bulkier reagent than the linear allyltrimethylsilane and in certain cases may also govern the stereochemical outcome of the investigated reactions. This might be the reason for the formation of product **38**; stereoelectronically favored addition of the nucleophile to the E₄ conformer of **45** is plausibly affected by steric repulsion between the bulky diene and the alkoxy substituent at the C-3 position.

Addition to imine **46** (Scheme 12), obtained from lactam **21**, gave compound **40** as the major isomer (Table 4, entry 10). For both compounds, the assignment of relative configuration between H-1 and H-8_{anti} by NOE experiments was impossible; the observed enhancement of signals was small and did not

enable unambiguous assignment of a configuration. However, an inspection of coupling constants of the protons at the C-8 position showed that one of them has an abnormally high value of ³J to the bridgehead H-8_a proton (16.3 Hz). On the basis of the Karplus equation, it was assumed that both hydrogen atoms have a plausibly antiperiplanar orientation (H-8_a and H-8_{anti}). The same observation was made for all compounds with an indolizidine scaffold (**7a–d**, **17–22**). The presence of this effect proved useful for the structure determination of compounds **7a–d** and **17–22**. According to this, for the major product (**40**) a 1,8_a-trans relation of protons was determined due to the presence of an NOE effect between H-8_{anti} and H-1 protons. In the case of the minor product **8a-epi-40**, there was an interaction between H-1 and H-8_a protons


Table 5. Effect of Diene Type on Stereoselectivity of Reduction/Mannich/Michael Tandem Reaction of Lactams 14 and 18^a



entry	lactam	R (diene)	major product	yield (%) ^b	d.r. (%) ^c
1	14	TMS	34	67	87:13
2	14	TBS	34	62	88:12
3	18	TMS	37	55	90:10
4	18	TBS	37	68	87:13

^aReaction conditions: (step 1) $\text{Cp}_2\text{Zr}(\text{H})\text{Cl}$ (1.6 equiv) in THF for 30 min; (step 2) diene (2 equiv), Lewis acid (10 mol%) at -25°C for 30 min and then 3 h at room temperature. ^bIsolated yield (overall after two steps). ^cDetermined by HPLC of the crude reaction mixture.

Scheme 7



and no NOE effect between H1/H-8_{anti}; therefore, a 1,8a-cis relative configuration was assigned.

The formation of the 1,8a-trans product **40** is in opposition to Woerpel's model for allylation of furanosyl oxycarbenium ions,^{46e} which assumes the formation of its epimer through syn addition to the E_4 conformer of imine **46** (Scheme 12). It seems that for 3-alkoxy-substituted imines, such as **46**, the addition is ruled again mainly by steric factors connected with steric repulsion of the bulky nucleophile and the substituent at C-3 position (Scheme 12).

Finally, for both 3,4,5-trisubstituted imines **6a** and **47**, an addition of DD provided compounds **7a** and **35**, respectively. In both cases the aforementioned compounds were formed with high stereoselectivity and, as assigned by NOE experiments, had a trans arrangement of protons at positions C-2 and C-8a (Schemes 13 and 14).

When addition to imine **6a** is considered through Woerpel's model, the low selectivity of the reaction should be expected, as is observed for allylation of arabinose-derived acetals.^{46e,48} For the C-4 alkoxy group to occupy the preferred pseudoaxial orientation, all substituents must be also pseudoaxial (E_4 conformer of **6a**; Scheme 13). However, such an arrangement is disfavored due to unfavorable *syn*-butanol interactions.⁴⁹ As a result, the reaction course via the all equatorially substituted conformer 4E should also be possible and, in consequence, lead

to a poorly selective reaction. Such is not, however, the case for imine **6a**; the high stereoselectivity of the reaction, leading mainly to product **7a**, indicates that the process is stereo-electronically controlled not only by the imine ("inside" approach of the nucleophile via E_4 conformer) but also by a steric effect of the bulky nucleophilic reagent.

The addition to imine **47** proceeded syn to the C-3 alkoxy group to provide compound **35** with a 2,8a-cis arrangement of protons (Scheme 14), and such an outcome corresponds well with Woerpel's rationalization.^{46e} This result is even more interesting if it is compared with the stereochemical outcome of the analogous reaction of imine **45** (Scheme 11). As already discussed, in the latter case the addition was mainly controlled by the sterics of the alkoxy group at C-3 of the imine, which resulted in the formation of 1,8a-trans-2,8a-trans product **38**. At this moment there is no reasonable explanation for this phenomenon. One can assume that observed differences may be result of the presence or absence of a CH_2OBn substituent at the C-5 position. However, as proved experimentally, this substituent has a minor influence on the course of the addition process to either imines (see Scheme 9) or furanosyl oxycarbenium ions.^{46e}


Stereochemistry of Reactions Involving Six-Membered Imines. As in the case of five-membered cyclic imines, Woerpel's model for addition to pyranosyl oxycarbenium ions^{46b,c,f} was used as a working model for the rationalization of the stereochemical outcome of the Mannich/Michael reaction of six-membered imines.

Nucleophile additions to six-membered oxocarbenium ions occur through chairlike transition structures, not twistlike ones, through an axial trajectory (Scheme 15).⁵⁰ As indicated by Woerpel and co-workers,^{46c,f,g} their stereochemical course is also governed by stereoelectronic effects. Thus, substrates bearing alkoxy groups at C-3, C-4, or C-5 give β isomers as the major products. Again, the preference to adopt an axial orientation of substituents at C-4 and C-5 and equatorial position by groups at C-3 was crucial (for the numbering of positions see Scheme 16).


As shown in Tables 2–4, the reaction of the model *gluco*-lactam **8** with DD gave the bicyclic product **10** with a cis arrangement of H-9 and H-9a protons (Scheme 16). The assignment of absolute configuration at H-9a was not easy task since, as concluded from NMR data, the *gluco* ring in **10** has a half-boat conformation. The assignment was proven by X-ray analysis of a hydrogenated derivative of **10** (compound **11**, Scheme 4).

The formation of the 9,9a-cis product **10** plausibly results from an axial attack of the nucleophile at the all-equatorial 4H_3 conformer (Scheme 16). The 3H_4 conformer, which bears stereoelectronically more preferred axially oriented C-3 and C-4 groups, is strongly destabilized by 1,3-diaxial interactions. The observed stereochemical outcome corresponds well to our


Scheme 8




Scheme 9




Scheme 10



Scheme 11



Scheme 12



previous studies of allylation of in situ generated sugar-derived imines (Scheme 17, eq 1)³⁹ as well as allylation of the *gluco*-oxycarbenium ion.^{46b,c,f}

The stereochemistry of the addition of DD to *manno*-imine **48** (Table 4, entry 2) differed from the outcome observed during its allylation (Scheme 17, eq 2)³⁹ and led to compound **32**, with a 9,9a-*trans* relative configuration, as the major isomer.

Conformational analysis showed that the ³H₄ conformer of **48** is only slightly less favored than the ⁴H₃ form (by 0.3 kcal/mol), what probably arises from destabilizing 1,3-diaxial interactions between substituents at C-3 and C-5. The nucleophile's approach from the more stereoelectronically favored face of ³H₄ (from the top, Scheme 18) would result in the development of a *syn*-pentane⁵¹ interaction between the nucleophile and the substituent at C-5 as well as a smaller *syn*-butane¹⁴⁹ interaction with the substituent at C-3. Such destabilizing interactions, as well as the small energy difference between both conformers, plausibly result in an interconverting mixture of conformers, and the reaction proceeds through the lowest-energy transition state via conformer ⁴H₃, in accordance with the Curtin–Hammett principle, leading to compound **32** as the major product (Scheme 18). The different stereochemical preferences of the addition of Danishefsky's diene and allyltributylstannane indicate that the type of nucleophile and its size and reactivity may also influence the course of the reaction. For the more bulky diene, the addition is plausibly governed by steric factors. Thus, the approach through ⁴H₃ is preferred. In the case of the ³H₄ conformer of **48**, an axial approach of the nucleophile may be effected by steric repulsion between the alkoxy group at C-3 or/and C-4. In the case of the more linear allylstannane, such an interaction may be weaker and, as a result, the addition proceeds through the stereoelectronically more preferred conformer ³H₄.


Interestingly, in contrast to *gluco*-imine **9**, nucleophile addition to *galacto*-imine **49** followed by intramolecular Michael conjugate addition gave product **9c** as the major isomer, with a *trans* arrangement of H-9 and H-9a protons (Table 4, entry 3). Such an outcome also differs from the result of allylation of *galacto*-imine **49** (Scheme 17, eq 3)³⁹ as well as syntheses of analogous *C*-glycosides of galactose.^{46f,52,53}

Computational studies showed a 1.5 kcal/mol energy difference between both conformers of imine **49** (Scheme 19). The addition of DD plausibly proceeds via the stereoelectronically more favored face of the ³H₄ conformer, which should result in the formation of the 9,9a-*trans* isomer as the predominant product.


In comparison to imines **9**, **48**, and **49**, the reaction of imine **50** with DD was slightly less selective (Table 4, entry 4). The major product was compound **34**, with a *trans* arrangement of H-9 and H-9a protons. Again, such a result was in opposition to the allylation of the same imine with allyltributylstannane (Scheme 17, eq 4).³⁹

The calculated energy difference between the two conformers of imine **50** is low and indicates the presence of their


Scheme 13




Scheme 14



Scheme 15



Scheme 16



interconverting mixture (Scheme 20). Woerpel's model assumes the axial approach of the nucleophile to the top face of 3H_4 conformer of **50** leading, as a result, to the formation of the 9,9a-cis isomer. Such an outcome was observed by us previously in the case of allylation of imine **50** (Scheme 17, eq 4).³⁹ However, the formation of compound **34** as the major isomer indicates that in the case of addition of DD to imine **50** the axial attack of the nucleophile through the 4H_3 conformer seems to be preferred. Although in this case the C-2 group occupies the disfavored axial position, such a location of the substituent minimizes any steric interaction which might occur during the axial approach of a rather bulky nucleophile (e.g., Danishefsky's diene). In case of the 3H_4 conformer of **50**, steric repulsion during the syn approach of the nucleophile may affect

the energy of the transition state, making it less preferred. Such experimental results additionally support the statement that the course of the investigated addition reaction depends on the size of the nucleophile as well.


CONCLUSION

In conclusion, an attractive method for the formation of indolizidine and quinolizidine scaffolds was developed. The presented strategy is based on a one-pot sugar-derived lactam reduction/Mannich/Michael tandem reaction. The availability of starting materials—sugar lactams—and the high stereoselectivity of the cyclocondensation step open a straightforward and general route to polyhydroxylated indolizidines and quinolizidines which not only provides complex 5,6- and 6,6-fused systems in a one-pot manner but also allows diverse iminosugars to be constructed in a common pathway. It is also worth emphasizing that the presence of an enaminone moiety in the resulting bicyclic products gives an opportunity for their further transformation/functionalization.


The use of sugar-derived lactams, as cyclic imine precursors, shows the crucial benefit of the disclosed synthetic method. These compounds are more easily and readily prepared, handled, and stored than the alternative precursors of cyclic imines such as nitrones, *N*-chloroamines, and azido aldehydes. As demonstrated, there is no need to isolate in situ generated imines, which can be directly used in subsequent reactions with Danishefsky's diene in the presence of a catalytic amount of a Lewis acid, such as $Yb(OTf)_3$ or TMSOTf.

As shown in the second part of the article, the stereochemical course of the investigated process, which is a stepwise aza-Mannich/Michael sequence, is determined by nucleophilic addition of DD to the in situ generated imines and is ruled not only by steric but also by stereoelectronic factors, as in the case of allylation of five- and six-membered oxycarbenium ions investigated in detail by the Woerpel group. As we pointed out, on the basis of a comparison of the current results with studies on the allylation of cyclic imines, the structure of the nucleophile is an additional factor which has an influence on the stereochemical outcome of the investigated process, giving new insights into the knowledge about addition to cyclic imines.


Scheme 17



Scheme 18



Scheme 19



TOF) m/z calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_3\text{Na}$ [$M + \text{Na}^+$] 334.1419, found 334.1423; IR (film) ν 3400, 3031, 2921, 2866, 1585, 1454, 1366, 1249, 1110, 738, 698 cm^{-1} .

Deoxygenation of Nitrones: General Procedure. To a stirred solution of nitrone (1.2 mmol) in THF (20 mL) under argon was added *n*-Bu₃P (2.0 equiv, 600 μL , 2.4 mmol) in one portion. The reaction mixture was heated to 75 °C for 24–72 h. The progress of the reaction was followed by TLC. After removal of the solvent, the crude product was chromatographed on Florisil.


(*2R,3R,4R*)-3,4-Bis(benzyloxy)-2-(benzyloxymethyl)-3,4-dihydro-2H-pyrrole (**6a**): colorless oil; isolated yield 400 mg (83%) starting from 500 mg (1.2 mmol) of nitrone **5a**; $[\alpha]_D^{25} -9.9$ (c 0.8, CH_2Cl_2) (lit.⁵⁴ $[\alpha]_D -10.4$ (c 0.8, CHCl_3)); $R_f = 0.35$ (100% Et₂O); column chromatography (100% Et₂O); ¹H NMR (600 MHz, CDCl_3) δ 7.60 (d, J 2.3 Hz, 1H), 7.37–7.25 (m, 15H), 4.62–4.52 (m, 7H), 4.16 (dt, J 7.8, 6.3 Hz, 1H), 4.11 (t, J 3.8 Hz, 1H), 3.76 (dd, J 9.8, 4.6 Hz, 1H), 3.54 (dd, J 9.8, 6.3 Hz, 1H); ¹³C NMR (126 MHz, CDCl_3) δ 165.9, 138.1, 137.8, 137.5, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 90.6, 84.3, 73.3, 72.2, 71.9, 70.9; HRMS (ESI-TOF) m/z

EXPERIMENTAL SECTION

Synthesis of Nitrones 5a–d. The known nitrones **5a**,³⁴ **5c**,^{14b} and **5d**^{14d} were prepared according to literature procedures. Compound **5b** was prepared following the synthetic procedure described by Maciejko et al.³⁶

(*2S,3S*)-3-(Benzyloxy)-2-(benzyloxymethyl)-3,4-dihydro-2H-pyrrole *N*-oxide (**5b**): prepared according to literature procedure;³⁶ white waxy solid; $[\alpha]_D^{25} +22.4$ (c 1.39, CHCl_3); ¹H NMR (600 MHz, CDCl_3) δ 7.34–7.23 (m, 10H), 6.88 (d, J 1.3 Hz, 1H), 4.62–4.58 (m, 2H), 4.58–4.54 (m, 2H), 4.48 (td, J 6.9, 4.9 Hz, 1H), 4.14–4.08 (m, 2H), 4.05–4.01 (m, 1H), 2.82 (ddd, J 17.9, 6.9, 2.6 Hz, 1H), 2.77–2.70 (m, 1H); ¹³C NMR (151 MHz, CDCl_3) δ 137.5, 137.4, 134.1, 128.5, 128.0, 127.9, 127.6, 127.5, 71.9, 71.8, 71.4, 70.4, 60.1; HRMS (ESI-

Scheme 20



calcd for $C_{26}H_{27}NO_3Na$ [$M + Na^+$] 424.1883, found 424.1894; IR (film) ν 2925, 2862, 1496, 1454, 1362, 1206, 1097, 1028, 736, 697 cm^{-1} .

(2*S*,3*S*)-3-(Benzyloxy)-2-(benzyloxymethyl)-3,4-dihydro-2*H*-pyrrole (**6b**): colorless oil; isolated yield 198 mg (67%) starting from 375 mg (1.2 mmol) of nitrone **5b**; $[\alpha]_D +14.7$ (*c* 1.0, CH_2Cl_2); $R_f = 0.22$ (5% MeOH in CH_2Cl_2); column chromatography (4/1 AcOEt/hexanes then 100% AcOEt); 1H NMR (400 MHz, $CDCl_3$) δ 7.69 (s, 1H), 7.41–7.24 (m, 11H), 4.66 (d, *J* 11.8 Hz, 1H), 4.60 (d, *J* 11.9 Hz, 1H), 4.54 (d, *J* 12.0 Hz, 1H), 4.47 (d, *J* 12.1 Hz, 1H), 4.25 (t, *J* 5.1 Hz, 1H), 4.07 (s, 1H), 4.00–3.90 (m, 2H); HRMS (ESI-TOF) *m/z* calcd for $C_{19}H_{21}NO_2Na$ [$M + Na^+$] 318.1456, found 318.1457; IR (film) ν 3029, 2913, 2861, 1496, 1453, 1362, 1099, 734, 696 cm^{-1} .

(3*R*,4*R*)-3,4-Di-*tert*-butoxy-3,4-dihydro-2*H*-pyrrole (**6c**): colorless oil; isolated yield 181 mg (85%) starting from 275 mg (1.2 mmol) of nitrone **5c**; $[\alpha]_D +68.9$ (*c* 1.5, CH_2Cl_2); $R_f = 0.43$ (100% AcOEt); column chromatography (7/3 AcOEt/hexanes); 1H NMR (600 MHz, $CDCl_3$) δ 7.50–7.49 (m, 1H), 4.49 (d, *J* 4.0 Hz, 1H), 4.09–4.04 (m, 2H), 3.57–3.51 (m, 1H), 1.25 (s, 9H), 1.19 (s, 9H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 168.6, 84.2, 77.9, 74.5, 73.8, 66.7, 28.5, 28.4; HRMS (ESI-TOF) *m/z* calcd for $C_{12}H_{24}NO_2$ [$M + H^+$] 214.18016, found 214.1799; IR (film) ν 2975, 1722, 1472, 1390, 1365, 1193, 1100, 888 cm^{-1} .

(*S*)-4-*tert*-Butoxy-3,4-dihydro-2*H*-pyrrole (**6d**): colorless oil; isolated yield 97 mg (69%) starting from 190 mg (1.2 mmol) of nitrone **5d**; $[\alpha]_D +20.1$ (*c* 0.6, CH_2Cl_2); $R_f = 0.35$ (100% acetone); column chromatography (1/1 AcOEt/hexanes then 100% AcOEt); 1H NMR (600 MHz, $CDCl_3$) δ 7.49 (t, *J* 2.2 Hz, 1H), 4.65 (dd, *J* 8.1, 6.4 Hz, 1H), 4.06–4.00 (m, 1H), 3.75–3.68 (m, 1H), 2.24–2.13 (m, 1H), 1.69–1.54 (m, 2H), 1.25 (s, 6H), 1.20 (s, 3H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 168.2, 78.1, 74.1, 60.1, 31.5, 28.7, 28.3; HRMS (ESI-TOF) *m/z* calcd for $C_8H_{16}NO$ [$M + H^+$] 142.1232, found 142.1248; IR (film) ν 2975, 1389, 1363, 1197, 1097, 1098, 888 cm^{-1} .

Danishefsky's Diene. To a solution of 4-methoxybut-3-en-2-one (9.5 mL, 94.0 mmol) in dry Et_2O (400 mL) was added Et_3N (32.9 mL, 236.0 mmol) under argon. The reaction mixture was cooled to 0 °C, and a solution of TMSOTf (19.6 mL, 108.0 mmol) in Et_2O (20 mL) was added dropwise. After it was stirred overnight at 0 °C, the reaction mixture was quenched by addition of saturated aqueous $NaHCO_3$ (100 mL, at 0 °C) followed by addition of pentane (100 mL). The organic layer was separated, and the aqueous layer was extracted with pentane (100 mL). The combined organic extracts were washed with saturated aqueous $NaHCO_3$ (2 \times 100 mL), water (2 \times 100 mL), and brine (2 \times 100 mL) and dried over Na_2SO_4 . The solvent was removed, and the resulting brown oil was distilled under reduced pressure (70 °C, 15 mbar) to afford 14.4 g of the diene (89%) as a colorless liquid.

The compound was stored under argon in a freezer: 1H NMR (400 MHz, $CDCl_3$) δ 6.82 (d, *J* 12.4 Hz, 1H), 5.35 (d, *J* 12.4 Hz, 1H), 4.10 (s, 1H), 4.06 (s, 1H), 3.58 (s, 3H), 0.23 (s, 9H).

TBS-Danishefsky's Diene. To a solution of 4-methoxybut-3-en-2-one (505 μ L, 5.0 mmol) in dry Et_2O (20 mL) was added Et_3N (1.75 mL, 12.6 mmol) under argon. The reaction mixture was cooled to 0 °C, and a solution of TBSOTf (1.3 mL, 5.74 mmol) in Et_2O (1 mL) was added dropwise. After it was stirred overnight at 0 °C, the reaction mixture was quenched with addition of saturated aqueous $NaHCO_3$ (10 mL, at 0 °C) followed by addition of pentane (20 mL). The organic layer was separated, and the aqueous layer was extracted with pentane (10 mL). The combined organic extracts were washed with aqueous $NaHCO_3$ (2 \times 10 mL), water (2 \times 10 mL), and brine (2 \times 10 mL) and dried over Na_2SO_4 . The solvent was removed, and the resulting brown oil was distilled under diminished pressure (71–72 °C, 3.8 Torr) to afford 808 mg of the diene (82%) as a colorless liquid. The reagent was stored under argon in the freezer: 1H NMR (200 MHz, $CDCl_3$) δ 7.11 (d, *J* 12.3 Hz, 1H), 5.58 (d, *J* 12.3 Hz, 1H), 4.30 (d, *J* 6.2 Hz, 2H), 3.81 (s, 3H), 1.19 (s, 9H), 0.42 (s, 6H).

Mannich/Michael Reaction of Cyclic Imines with Danishefsky-Type Dienes: General Procedure. To a solution of the imine (0.5 mmol) in dry CH_2Cl_2 (5 mL) was added $Yb(OTf)_3$ (10 mol%, 31 mg, 0.05 mmol) at –25 °C under argon. The mixture was stirred for 10 min at the same temperature, and then Danishefsky's diene (1.2 equiv, 117 μ L, 0.6 mmol) was added dropwise. The mixture was warmed gradually to room temperature. After it was stirred for 2.5 h at room temperature (TLC monitoring), the reaction mixture was quenched with 1 M aqueous HCl (1 mL) and diluted with CH_2Cl_2 (3 mL). After phase separation, the organic layer was washed with water (3 mL) and brine (3 mL), dried over Na_2SO_4 , and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography to give the corresponding bicyclic product(s).

(1*R*,2*R*,3*R*,8*aR*)-1,2-Bis(benzyloxy)-3-(benzyloxymethyl)-2,3,8,8a-tetrahydroindolizin-7(1*H*)-one (**7a** and **8a-epi-7a**): inseparable mixture of diastereomers; colorless oil; for yield and *d.r.* see Tables 2 and 4; column chromatography (7/3 AcOEt/hexanes); major isomer **7a** (pure sample obtained by preparative TLC, Merck preparative TLC plates Si60 F254, 20 \times 20 cm, hexanes/AcOEt 1/1) $[\alpha]_D -191.7$ (*c* 0.15, CH_2Cl_2); $R_f = 0.32$ (7/3 AcOEt/hexanes); 1H NMR (600 MHz, C_6D_6) δ 6.94–6.80 (m, 15H, 3 \times Ph), 6.48 (d, *J* 7.3 Hz, 1H, $CH=CHC=O$), 4.82 (d, *J* 7.3 Hz, 1H, $CH=CHC=O$), 4.09 (d, *J* 11.9 Hz, 1H, PhCHHO), 4.04 (d, *J* 11.9 Hz, 1H, PhCHHO), 4.02 (d, *J* 11.7 Hz, 1H, PhCHHO), 3.97 (d, *J* 11.7 Hz, 1H, PhCHHO), 3.85 (m, 2H, PhCH₂O), 3.53 (ps t, *J* 4.3, 4.0, 1H, H-2), 3.43 (dd, *J* 6.9, 4.3 Hz, 1H, H-1), 3.38 (dt, *J* 16.1, 6.7, 5.1 Hz, 1H, H-8a), 3.17–3.13 (m, *J* 6.5, 4.8, 4.0 Hz, 1H, H-3), 2.82 (dd, *J* 10.0, 4.8 Hz, 1H, CHHOBn), 2.79 (dd, *J* 10.0, 6.5 Hz, 1H, CHHOBn), 2.24 (dd, *J* 15.9, 5.1 Hz, 1H, H-8_{syn}), 2.03 (ps t, *J* 16.1, 15.9 Hz, 1H, H-8_{anti}); ^{13}C NMR (126 MHz, $CDCl_3$) δ 191.2, 149.8, 137.3, 137.2, 128.6, 128.5, 128.12, 128.07, 128.0, 127.8, 127.7, 98.1, 87.9, 84.2, 73.4, 72.6, 72.3, 69.3, 64.6, 61.4, 40.6; minor isomer **8a-epi-7a** selected signals 1H NMR (500 MHz, C_6D_6) δ 6.61 (d, *J* 7.3 Hz, 1H, $CH=CHC=O$), 4.88 (d, *J* 7.3 Hz, 1H, $CH=CHC=O$), 3.26 (m, 1H, H-8a), 2.95 (dd, *J* 7.4, 2.7 Hz, 1H, CHHOBn), 2.53 (t, *J* 16.3, 16.0 Hz, 1H, H-8_{anti}), 1.97 (dd, *J* 16.0, 4.6 Hz, 1H, H-8_{syn}); HRMS (ESI-TOF) *m/z* calcd for $C_{30}H_{31}NO_4Na$ [$M + Na^+$] 492.2145, found 492.2167; IR (film) ν 2864, 1638, 1577, 1454, 1115, 1096, 740, 698 cm^{-1} ; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 0.5 mL/min, UV 313 nm, R_t 23.1 min (**7a** major isomer), 35.8 min (**8a-epi-7a** minor isomer).

(2*S*,3*S*,8*aS*)-2-(Benzyloxy)-3-(benzyloxymethyl)-2,3,8,8a-tetrahydroindolizin-7(1*H*)-one (**7b** and **8a-epi-7b**): inseparable mixture of diastereomers; colorless oil; isolated yield 99 mg (55%, both isomers) starting from 150 mg (0.5 mmol) of imine **6b**; *d.r.* 86:14 (determined by 1H NMR of crude reaction mixture); column chromatography (100% AcOEt); major isomer **7b** (pure sample after preparative TLC, Merck preparative TLC plates Si60 F254, 20 \times 20 cm, hexanes/AcOEt 1/9) $[\alpha]_D -190.7$ (*c* 2.87, CH_2Cl_2); $R_f = 0.22$ (100% AcOEt); 1H NMR (600 MHz, $CDCl_3$) δ 7.39–7.19 (m, 11H, 2 \times Ph, $CH=CHC=O$), 4.99 (d, *J* 7.2 Hz, 1H, $CH=CHC=O$), 4.58–4.56 (m,

2H, OCH₂Ph), 4.53–4.49 (m, 2H, OCH₂Ph), 4.26–4.20 (m, 1H, H-8a), 3.86 (td, *J* 8.5, 7.1, 3.3 Hz, 1H, H-3), 3.77 (dd, *J* 10.0, 3.3 Hz, 1H, CHHOBn), 3.75–3.71 (m, 1H, H-2), 3.52 (dd, *J* 10.0, 8.5 Hz, 1H, CHHOBn), 2.41 (dt, *J* 12.3, 6.2 Hz, 1H, H-1), 2.38–2.34 (m, 2H, H-8', H-8''), 1.85–1.75 (m, 1H, H-1'); ¹³C NMR (151 MHz, CDCl₃) δ 192.3, 150.7, 137.7, 137.4, 128.53, 128.45, 128.0, 127.8, 127.7, 127.5, 98.5, 73.6, 72.3, 70.4, 60.8, 55.7, 42.1, 36.3; minor isomer **8a-epi-7b** selected signals ¹H NMR (600 MHz, CDCl₃) δ 4.95 (d, *J* 7.3 Hz, 1H), 4.15–4.10 (m, 1H, H-3); minor isomer **8a-epi-7b** selected signals ¹³C NMR (151 MHz, CDCl₃) δ 191.5, 149.8, 137.6, 137.5, 97.6, 78.0, 73.6, 71.5, 69.7, 63.5, 55.9, 41.4, 36.7; HRMS (ESI-TOF) *m/z* calcd for C₂₃H₂₅NO₃Na [M + Na⁺] 386.1745, found 386.1745; IR (film) ν 2922, 2866, 1634, 1571, 1453, 1335, 1096, 738, 698 cm⁻¹.

(1*R*,2*R*,8*aR*)-1,2-Di-*tert*-butoxy-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**7c** and **8a-epi-7c**): inseparable mixture of diastereomers; isolated yield 96 mg (69%, both isomers) starting from 135 mg (0.5 mmol) of imine **6c**; *d.r.* 86:14 (determined by HPLC of crude reaction mixture); *R*_f = 0.22 (100% AcOEt); column chromatography (4/1 AcOEt/hexanes); major isomer **7c** (pure sample prepared by preparative TLC, Merck preparative TLC plates Si60 F254, 20 × 20 cm, hexanes/AcOEt 1/1); colorless oil; [α]_D²⁰ +280.6 (c 0.9, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 7.05 (d, *J* 7.1 Hz, 1H), 4.95 (d, *J* 7.1 Hz, 1H), 3.98 (dd, *J* 12.3, 5.9 Hz, 1H), 3.88–3.84 (m, 1H), 3.73–3.68 (m, 1H), 3.57 (dt, *J* 15.5, 6.3 Hz, 1H), 3.26 (dd, *J* 10.7, 5.8 Hz, 1H), 2.55–2.44 (m, 2H), 1.20 and 1.18 (2 × s, 18H); ¹³C NMR (151 MHz, CDCl₃) δ 191.9, 150.4, 97.7, 75.5, 74.6, 74.2, 61.0, 54.9, 39.5, 29.0, 28.4; minor isomer **8a-epi-7c** selected signals: ¹H NMR (600 MHz, CDCl₃) δ 7.15 (d, *J* 7.0 Hz, 1H); HRMS (EI) *m/z* calcd for C₁₆H₂₇O₃N [M⁺] 281.1990, found 281.1985; IR (film) ν 2975, 1637, 1579, 1364, 1191, 1092 cm⁻¹; HPLC Chiralpak OD-H, 20% *i*-PrOH in hexanes, flow 1.0 mL/min, UV 335 nm, *R*_f 4.9 min (minor isomer **8a-epi-7c**), 8.1 min (major isomer **7c**).

(1*S*,8*aR*)-1-*tert*-Butoxy-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**7d** and **8a-epi-7d**): mixture of diastereomers; isolated yield 67 mg (64%, both isomers) starting from 70 mg (0.5 mmol) of imine **6d**; *d.r.* 92:8 (determined by HPLC of crude reaction mixture); column chromatography (100% AcOEt); major isomer **7d**; colorless oil; [α]_D²⁰ -25.6 (c 0.9, CH₂Cl₂); (Lit.⁵⁵ [α]_D²⁰ -28.3 (c 0.5, CH₂Cl₂)); *R*_f = 0.20 (100% AcOEt); ¹H NMR (600 MHz, CDCl₃) δ 7.08 (t, *J* 9.4 Hz, 1H), 4.94 (d, *J* 7.1 Hz, 1H), 3.98 (dd, *J* 15.2, 7.8 Hz, 1H), 3.60 (td, *J* 10.2, 3.6 Hz, 1H), 3.57–3.52 (m, 1H), 3.47 (dd, *J* 18.3, 9.2 Hz, 1H), 2.56 (dd, *J* 15.9, 5.0 Hz, 1H), 2.33 (t, *J* 16.2 Hz, 1H), 2.27 (ddd, *J* 12.4, 7.4, 3.5 Hz, 1H), 1.90 (ddd, *J* 17.7, 12.7, 9.2 Hz, 1H), 1.20 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 191.8, 150.3, 97.6, 76.4, 74.0, 62.1, 47.3, 39.5, 33.3, 28.4; minor isomer **8a-epi-7d** selected signals ¹H NMR (600 MHz, CDCl₃) δ 7.19 (d, *J* 7.2 Hz, 1H), 4.92 (d, *J* 7.0 Hz, 1H); HRMS (ESI-TOF) *m/z* calcd for C₁₂H₁₉NO₂Na [M + Na⁺] 232.1308, found 232.1305; IR (film) ν 2974, 1634, 1578, 1097 cm⁻¹; HPLC Chiralpak OD-H, 20% *i*-PrOH in hexanes, flow 1.0 mL/min, UV 329 nm, *R*_f 9.3 min (major isomer **7d**), 15.5 min (minor isomer **8a-epi-7d**).

(3*R*,4*R*)-3,4-Bis(benzyloxy)-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (**23**): prepared according to the literature procedure.⁴⁴

(3*R*,4*R*,5*S*)-3,4-Bis(benzyloxy)-5-hydroxy-1-(4-methoxybenzyl)pyrrolidin-2-one (**24** and **5-epi-24**). To a solution of **23** (1.764 g, 4.09 mmol) in dry MeOH (14 mL) and CH₂Cl₂ (25 mL) was added NaBH₄ (1.2 equiv, 186 mg, 4.91 mmol) in small portions at -78 °C. The reaction mixture was warmed quickly to room temperature and stirred for 12 h. When the reaction was complete (TLC 2/5 AcOEt/hexanes; *R*_f = 0.45), it was quenched by slow addition of H₂O (10 mL) at 0 °C. After phase separation, the aqueous phase was washed with CH₂Cl₂ (3 × 10 mL). The combined organic solutions were washed with H₂O (10 mL) and dried over Na₂SO₄. The crude mixture of products was used directly in the next step: inseparable mixture of diastereomers; colorless oil; isolated yield 89% (both isomers); *d.r.* 86:14 (determined by ¹H NMR of crude reaction mixture); major isomer **24** ¹H NMR (600 MHz, CDCl₃) δ 7.40–7.24 (m, 8H), 7.20 (dd, *J* 7.2, 4.8 Hz, 4H), 6.84–6.81 (m, 2H), 4.98 (d, *J* 11.7 Hz, 1H), 4.84 (d, *J* 14.6 Hz, 1H), 4.76 (d, *J* 11.6 Hz, 2H), 4.55 (d, *J* 11.7 Hz, 1H), 4.49 (d, *J* 11.7 Hz, 1H), 4.11 (d, *J* 14.6 Hz, 1H), 4.08 (d, *J* 4.6 Hz, 1H), 3.90 (dd, *J* 4.5, 2.9 Hz, 1H), 3.76 (s, 3H); ¹³C NMR (151 MHz,

CDCl₃) δ 169.9, 159.2, 137.2, 137.1, 129.8, 128.5, 128.4, 128.3, 128.0, 127.9, 127.7, 127.7, 114.1, 84.7, 83.9, 79.6, 72.9, 72.1, 55.3, 42.4; **5-epi-24** selected signals ¹H NMR (600 MHz, CDCl₃) δ 5.05 (d, *J* 11.7 Hz, 1H); HRMS (ESI-TOF) *m/z* calcd for C₂₆H₂₇NO₃Na [M + Na⁺] 456.1787, found 456.1789; IR (film) ν 3348, 2925, 1683, 1513, 1454, 1247, 1105, 738, 697 cm⁻¹.

(2*S*,3*R*,4*R*)-3,4-Bis(benzyloxy)-1-(4-methoxybenzyl)-5-oxopyrrolidin-2-yl acetate (**25** and **2-epi-25**). To a solution of **24**/**5-epi-24** (1.57g, 3.62 mmol) in dry CH₂Cl₂ (35 mL) were added Et₃N (9.0 equiv, 3.24 mL, 21.73 mmol) and Ac₂O (6.0 equiv, 2.0 mL, 21.73 mmol). The reaction mixture was stirred at room temperature for 12 h. The progress of the reaction was followed by TLC (1/3 AcOEt/hexanes, *R*_f = 0.35). Afterward, the solvent was removed under diminished pressure and the residue was chromatographed on silica gel (1/5 AcOEt/hexanes) to afford 1.19 g of the product (69% diastereoisomeric mixture, *d.r.* 89:2:10.8 based on ¹H NMR spectra of crude mixture) as a colorless oil: major isomer **25** ¹H NMR (600 MHz, CDCl₃) δ 7.40–7.34 (m, 5H), 7.32–7.27 (m, 4H), 7.21–7.17 (m, 2H), 7.17–7.14 (m, 2H), 6.84–6.81 (m, 2H), 4.97 (d, *J* 11.9 Hz, 1H), 4.77 (d, *J* 11.9 Hz, 1H), 4.62 (d, *J* 12.9 Hz, 1H), 4.54 (d, *J* 7.3 Hz, 1H), 4.48–4.46 (m, 1H), 4.20 (d, *J* 14.9 Hz, 1H), 4.07 (d, *J* 2.8 Hz, 1H), 3.91 (dd, *J* 2.8, 1.5 Hz, 1H), 3.77 (s, 3H), 1.90 (s, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 171.2, 170.1, 159.2, 137.2, 136.9, 129.5, 128.4, 128.2, 128.0, 127.9, 127.8, 127.7, 114.0, 84.7, 81.6, 79.4, 72.7, 71.9, 55.2, 43.9, 20.8; minor isomer **2-epi-25** selected signals ¹H NMR (600 MHz, CDCl₃) δ 4.94 (d, *J* 11.8 Hz, 1H), 4.82 (d, *J* 11.7 Hz, 1H), 4.66 (d, *J* 14.7 Hz, 1H), 3.93 (dd, *J* 2.7, 1.4 Hz, 1H); HRMS (ESI-TOF) *m/z* calcd for C₂₈H₂₉NO₆Na [M + Na⁺] 498.1893, found 498.1894; IR (film) ν 3032, 2934, 1716, 1514, 1248, 1226, 1177, 1108, 1019, 738, 698 cm⁻¹.

(3*R*,4*R*)-5-Acetoxy-3,4-bis(benzyloxy)-*N*-(4-methoxybenzyl)-pyrrolidin-2-one (**26**). To a **25**/**2-epi-25** mixture (709 mg 1.49 mmol) in dry CH₂Cl₂ (20 mL) at -78 °C was added BF₃·Et₂O (2.0 equiv, 374 μL, 2.98 mmol). The mixture was stirred for 30 min, and then Et₃SiH (5.0 equiv, 1.2 mL, 7.45 mmol) was added. The mixture was warmed to room temperature and quenched by saturated aqueous Na₂CO₃ (5 mL). After phase separation, the aqueous phase was washed with CH₂Cl₂ (10 mL). The combined organic phases were dried over Na₂SO₄. The crude product (590 mg, 95%, colorless oil) was used directly in the next step. A pure sample was obtained by filtration through a short pad of silica gel (CH₂Cl₂): [α]_D²⁰ +73.8 (c 6.1, CHCl₃); (lit.⁵⁶ [α]_D²⁰ +77.5 (c 7.0, CHCl₃)); ¹H NMR (600 MHz, CDCl₃) δ 7.44–7.41 (m, 2H), 7.37–7.22 (m, 7H), 7.16–7.13 (m, 2H), 6.85–6.83 (m, 2H), 5.12 (d, *J* 11.6 Hz, 1H), 4.84 (d, *J* 11.6 Hz, 1H), 4.53 (d, *J* 11.6 Hz, 1H), 4.47 (d, *J* 11.6 Hz, 1H), 4.38 (s, 2H), 4.23 (d, *J* 5.7 Hz, 1H), 4.14 (dt, *J* 7.5, 5.8 Hz, 1H), 3.78 (s, 3H), 3.40 (dd, *J* 10.0, 7.6 Hz, 1H), 3.06 (dd, *J* 10.1, 5.8 Hz, 1H); ¹³C NMR (151 MHz, CDCl₃) δ 170.6, 159.2, 137.7, 137.4, 129.6, 128.4, 128.4, 128.3, 127.9, 127.9, 127.7, 127.6, 114.1, 80.8, 77.5, 72.5, 71.8, 55.3, 48.5, 45.8; HRMS (ESI-TOF) *m/z* calcd for C₂₆H₂₇NO₄Na [M + Na⁺] 440.1838, found 440.1838; IR (film) ν 2869, 1701, 1513, 1248, 1109, 1029, 738, 698 cm⁻¹.

(3*R*,4*S*)-3,4-Bis(benzyloxy)pyrrolidin-2-one (**18**). To a solution of **26** (408 mg, 0.89 mmol) in dry acetonitrile (9 mL) at 0 °C was added a solution of cerium ammonium nitrate (5.0 equiv, 2.44 g, 4.46 mmol) in H₂O (1 mL). After it was stirred for 6 h at 0 °C (TLC 1/2 AcOEt/hexanes), the reaction mixture was warmed to room temperature, and the organic layer was separated. The aqueous phase was washed with AcOEt (3 × 5 mL). The combined organic layers were washed with saturated aqueous NaHCO₃ (10 mL) and dried over Na₂SO₄. The crude product was purified by column chromatography on silica gel (1/2 AcOEt/hexanes) to give 177 mg of **18** (73%) as a yellow waxy solid: *R*_f = 0.15; [α]_D²⁰ +81.7 (c 1.23, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 7.42–7.39 (m, 2H), 7.36–7.32 (m, 3H), 7.31–7.27 (m, 5H), 6.39 (s, 1H), 5.07 (t, *J* 9.7 Hz, 1H), 4.80 (d, *J* 11.7 Hz, 1H), 4.59 (d, *J* 11.7 Hz, 1H), 4.52 (d, *J* 11.7 Hz, 1H), 4.27 (dd, *J* 13.8, 6.3 Hz, 1H), 4.17 (d, *J* 6.3 Hz, 1H), 3.57–3.52 (m, 2H), 3.17 (dd, *J* 9.8, 6.3 Hz, 1H); ¹³C NMR (151 MHz, CDCl₃) δ 173.9, 137.5, 137.4, 128.5, 128.4, 128.2, 127.90, 127.86, 127.80, 79.8, 79.6, 72.5, 71.9, 44.5;

HRMS (ESI-TOF) m/z calcd for $C_{18}H_{19}NO_3Na$ [$M + Na^+$] 320.1263, found 320.1266; IR (film) ν 3245, 2874, 1714, 1111, 737, 697 cm^{-1} .

(3*R*,4*R*)-3,4-Bis(benzyloxy)pyrrolidin-2-one (**19**). prepared according to the literature procedure;³⁹ white waxy solid, $[\alpha]_D +57.6$ (c 0.61, $CHCl_3$); $R_f = 0.47$ (100% AcOEt); column chromatography (1/1 then 4/1 AcOEt/hexanes); 1H NMR (600 MHz, $CDCl_3$) δ 7.42–7.26 (m, 10H), 6.57 (s, 1H), 5.05 (d, J 11.7 Hz, 1H), 4.80 (d, J 11.7 Hz, 1H), 4.58 (d, J 11.7 Hz, 1H), 4.52 (d, J 11.7 Hz, 1H), 4.26 (dd, J 13.7, 6.4 Hz, 1H), 4.17 (d, J 6.4 Hz, 1H), 3.54 (ddd, J 9.3, 7.6, 1.4 Hz, 1H), 3.15 (dd, J 9.8, 6.4 Hz, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 173.9, 137.6, 137.4, 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 79.9, 79.6, 72.5, 71.9, 44.5; HRMS (ESI-TOF) m/z calcd for $C_{18}H_{19}NO_3Na$ [$M + Na^+$] 320.1263, found 320.1263; IR (film) ν 3243, 2873, 1712, 1110, 738, 697 cm^{-1} .

(*R*)-3-Hydroxy-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (**27**). prepared according to the literature procedure;⁵⁷ $[\alpha]_D -66.0$ (c 0.84, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$) δ 7.34–7.29 (m, 2H), 6.95–6.70 (m, 2H), 4.69–4.52 (m, 3H), 3.78 (s, 3H), 3.29 (s, 1H), 3.04 (dd, J 18.2, 8.4 Hz, 1H), 2.66 (dd, J 18.2, 4.8 Hz, 1H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 177.9, 173.7, 159.4, 130.4, 127.5, 114.0, 67.0, 55.3, 42.0, 37.1; HRMS (ESI-TOF) m/z calcd for $C_{18}H_{19}NO_3Na$ [$M + Na^+$] 320.1263, found 320.1263; IR (film) ν 3435, 2943, 1698, 1514, 1248, 1107 cm^{-1} .

(*R*)-3-(Benzyloxy)-1-(4-methoxybenzyl)pyrrolidine-2,5-dione (**28**). To a solution of **27** (2.74 g, 11.65 mmol) in dry Et_2O (100 mL) were added BnBr (3.0 equiv, 4.15 mL, 34.89 mmol) and Ag_2O (3.6 equiv, 9.80 g, 42.29 mmol). After it was stirred overnight in the dark, the mixture was filtered through a pad of Celite. The collected solid was washed with AcOEt (50 mL), and the solvent was evaporated. The residue was chromatographed on silica gel (1/4 than 1/3 AcOEt/hexanes) to give 3.524 g of product **28** as a colorless oil: isolated yield 93%; $[\alpha]_D -73.3$ (c 0.81, $CHCl_3$); $R_f = 0.57$ (4/6 AcOEt/hexanes); 1H NMR (600 MHz, $CDCl_3$) δ 7.37–7.29 (m, 7H), 6.84–6.79 (m, 2H), 4.97 (d, J 11.7 Hz, 1H), 4.77 (d, J 11.7 Hz, 1H), 4.63–4.54 (m, 2H), 4.33 (dd, J 8.2, 4.2 Hz, 1H), 3.77 (s, 3H), 2.91 (dd, J 18.2, 8.2 Hz, 1H), 2.63 (dd, J 18.2, 4.2 Hz, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 175.6, 173.8, 159.3, 136.7, 130.4, 128.6, 128.23, 128.18, 127.7, 114.0, 73.0, 72.1, 55.2, 41.7, 36.3; HRMS (ESI-TOF) m/z calcd for $C_{19}H_{19}NO_4Na$ [$M + Na^+$] 348.1212, found 348.1210; IR (film) ν 2937, 1709, 1514, 1249, 699 cm^{-1} .

(3*R*)-3-(Benzyloxy)-1-(4-methoxybenzyl)-5-oxopyrrolidin-2-yl Acetate (**29**). To a solution of **28** (3.12 g, 9.59 mmol) in dry CH_2Cl_2 (41 mL) was added a 1 M solution of $LiEt_3BH$ in THF (11.3 mL, 95 mmol) dropwise at $-78^\circ C$. After the mixture was stirred for 15 min at $-78^\circ C$, Ac_2O (1.26 mL, 13.3 mmol) was added dropwise. Then the reaction mixture was warmed to ambient temperature and stirred overnight. The reaction progress was monitored by TLC (2/3 AcOEt/hexanes). At the end of the reaction activated carbon was added and the mixture was stirred for 15 min and then filtered through a pad of Celite. The collected solid was washed with AcOEt (30 mL), and the solvent was evaporated. The residue was chromatographed on silica gel (3/7 AcOEt/hexanes) to give 3.224 g of acetate **29** as a colorless oil: isolated yield 91%; $R_f = 0.34$; $[\alpha]_D -50.6$ (c 0.90, $CHCl_3$); 1H NMR (600 MHz, $CDCl_3$) δ 7.34–7.29 (m, 2H), 7.29–7.23 (m, 3H), 7.19–7.14 (m, 2H), 6.86–6.80 (m, 2H), 6.23 (d, J 5.0 Hz, 1H), 4.67 (d, J 14.6 Hz, 1H), 4.52 (d, J 11.7 Hz, 1H), 4.44 (d, J 11.7 Hz, 1H), 4.13–4.05 (m, 2H), 3.78 (s, 3H), 2.61 (d, J 8.6 Hz, 2H), 1.97 (s, 3H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 172.3, 170.7, 159.2, 137.1, 129.8, 128.5, 128.1, 128.0, 127.6, 114.1, 81.5, 72.17, 72.16, 55.3, 44.0, 35.0, 20.8; HRMS (ESI-TOF) m/z calcd for $C_{21}H_{23}NO_5Na$ [$M + Na^+$] 392.1474, found 392.1472; IR (film) ν 2934, 1742, 1715, 1514, 1248, 1230, 1179, 1029, 966 cm^{-1} .

(*R*)-4-(Benzyloxy)-1-(4-methoxybenzyl)pyrrolidin-2-one (**30**) and (*R*)-3-(Benzyloxy)-1-(4-methoxybenzyl)pyrrolidin-2-one (**31**). To a solution of **29** (3.26 g, 8.83 mmol) in dry CH_2Cl_2 (117 mL) was added $BF_3 \cdot Et_2O$ (2.0 equiv, 2.2 mL, 17.5 mmol) dropwise at $-78^\circ C$. After the mixture was stirred for 30 min, Et_3SiH (5 equiv, 7.0 mL, 31.3 mmol) was added dropwise. After this mixture was stirred for an additional 30 min, the cooling bath was removed and the reaction mixture was left overnight at room temperature. The reaction progress

was monitored by TLC (2/3 AcOEt/hexanes). The reaction was quenched with saturated aqueous Na_2CO_3 (50 mL). The organic layer was separated, and the aqueous layer was extracted with CH_2Cl_2 (50 mL). The combined organic extracts were dried over Na_2SO_4 . After removal of solvent the residue was chromatographed on silica gel (2/3 AcOEt/hexanes) to give 2.248 g of **30** (yield 82%) and 143 mg of **31** (yield 5%) Compound **30**: $R_f = 0.1$ (2/3 AcOEt/hexanes); $[\alpha]_D +8.4$ (c 0.36, $CHCl_3$); 1H NMR (600 MHz, $CDCl_3$) δ 7.35–7.30 (m, 2H), 7.29–7.21 (m, 3H), 7.18–7.12 (m, 2H), 6.87–6.81 (m, 2H), 4.48 (d, J 11.7 Hz, 1H), 4.42 (d, J 11.7 Hz, 1H), 4.40 (s, 2H), 4.18 (m, 1H), 3.78 (s, 3H), 3.43 (dd, J 10.8, 6.2 Hz, 1H), 3.28 (dd, J 10.8, 2.9 Hz, 1H), 2.67 (dd, J 17.3, 7.0 Hz, 1H), 2.57 (dd, J 17.3, 3.4 Hz, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 172.2, 159.1, 137.4, 129.4, 128.5, 128.2, 127.9, 127.6, 114.1, 70.9, 70.8, 55.3, 52.6, 45.6, 38.2; HRMS (ESI-TOF) m/z calcd for $C_{19}H_{21}NO_3Na$ [$M + Na^+$] 334.1419, found 334.1422; IR (film) ν 2932, 1687, 1513, 1247, 1031 cm^{-1} . Compound **31**: $R_f = 0.31$ (2/3 AcOEt/hexanes); $[\alpha]_D -73.1$ (c 1.02, $CHCl_3$); 1H NMR (600 MHz, $CDCl_3$) δ 7.42–7.37 (m, 2H), 7.36–7.31 (m, 2H), 7.29–7.24 (m, 1H), 7.18–7.13 (m, 2H), 6.87–6.81 (m, 2H), 5.00 (d, J 11.9 Hz, 1H), 4.77 (d, J 11.9 Hz, 1H), 4.40 (d, J 14.5 Hz, 1H), 4.37 (d, J 14.5 Hz, 1H), 4.13 (dd, J 7.7, 6.9 Hz, 1H), 3.77 (s, 3H), 3.24 (ddd, J 9.7, 8.8, 3.9 Hz, 1H), 3.11–3.01 (m, 1H), 2.27–2.17 (m, 1H), 1.98–1.90 (m, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 172.4, 159.1, 137.9, 129.5, 128.4, 128.1, 128.0, 127.7, 114.1, 75.9, 72.0, 55.3, 46.1, 43.1, 26.4; HRMS (ESI-TOF) m/z calcd for $C_{19}H_{21}NO_3Na$ [$M + Na^+$] 334.1419, found 334.1414; IR (film) ν 2935, 1693, 1513, 1247, 1030 cm^{-1} .

(*R*)-4-(Benzyloxy)pyrrolidin-2-one (**20**). To a solution of **30** (2.248 g, 7.22 mmol) in MeCN (70 mL) was added a mixture of CAN (5 equiv, 19.8 g, 36.1 mmol) and water (8.4 mL) portionwise at $0^\circ C$. The reaction mixture was warmed to room temperature and stirred overnight. The progress of the reaction was monitored by TLC (100% AcOEt). The reaction mixture was diluted with H_2O (20 mL) and extracted with AcOEt (20 mL). The organic layer was washed with saturated aqueous $NaHCO_3$ (20 mL) and dried over Na_2SO_4 , and the solvent was removed under diminished pressure. The crude product was purified by column chromatography (1/1 AcOEt/hexanes, 100% AcOEt, and then 5/95 MeOH/ CH_2Cl_2) to give 1.187 g of product **20**: yield 86%; $[\alpha]_D +2.4$ (c 0.88, $CHCl_3$); $R_f = 0.4$ (100% AcOEt); 1H NMR (600 MHz, $CDCl_3$) δ 7.35–7.26 (m, 5H), 6.86 (s, 1H), 4.48 (q, J 11.7 Hz, 2H), 4.27 (dq, J 9.5, 3.2 Hz, 1H), 3.56 (dd, J 10.6, 6.2 Hz, 1H), 3.40 (dd, J 10.6, 2.6 Hz, 1H), 2.55 (dd, J 17.3, 6.9 Hz, 1H), 2.43 (dd, J 17.3, 3.6 Hz, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 176.6, 137.5, 128.5, 127.9, 127.7, 73.8, 71.0, 48.8, 37.3; HRMS (ESI-TOF) m/z calcd for $C_{11}H_{13}NO_2Na$ [$M + Na^+$] 214.0844, found 214.0842; IR (film) ν 3236, 2916, 1693, 1667, 1354, 1095, 728 cm^{-1} .

(*R*)-3-(Benzyloxy)pyrrolidin-2-one (**21**): prepared following the procedure for the synthesis of **20**: isolated yield 76%; $[\alpha]_D -125.2$ (c 0.29, $CHCl_3$); $R_f = 0.19$ (100% AcOEt); 1H NMR (600 MHz, $CDCl_3$) δ 7.41–7.24 (m, 5H), 6.64 (s, 1H), 4.94 (d, J 11.9 Hz, 1H), 4.74 (d, J 11.9 Hz, 1H), 4.10–4.03 (m, 1H), 3.43 (td, J 9.0, 3.8 Hz, 1H), 3.27 (dt, J 9.7, 7.2 Hz, 1H), 2.36 (dtd, J 13.0, 7.6, 3.8 Hz, 1H), 2.11 (ddt, J 13.5, 8.4, 7.0 Hz, 1H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 176.3, 137.8, 128.4, 128.0, 127.8, 74.8, 72.1, 39.0, 28.8; HRMS (ESI-TOF) m/z calcd for $C_{11}H_{13}NO_2Na$ [$M + Na^+$] 214.0844, found 214.0843; IR (film) ν 3244, 2894, 1708, 1454, 1297, 1125, 741, 699 cm^{-1} .

(4*S*,5*R*)-4-Benzyloxy-5-benzyloxymethylpyrrolidin-2-one (**17**): prepared according to the literature procedure.^{39,58}

(*S*)-5-((*tert*-Butyldiphenylsilyloxy)methyl)pyrrolidin-2-one (**22**): prepared according to the literature procedure.^{59–62}

Dicyclopentadienylzirconium Hydrochloride (Schwartz's Reagent).⁶³ A solution of Cp_2ZrCl_2 (10.0 g, 34.2 mmol) in dry THF (65 mL) was stirred under argon in a Schlenk tube (covered with aluminum foil) until all solids dissolved. Then a 2 M solution of $LiAlH_4$ in THF (4.6 mL, 9.23 mmol) was added dropwise. The mixture was stirred for 90 min at room temperature. The white precipitate was filtered off under argon and, under argon, washed with dry THF (4 \times 20 mL), dry CH_2Cl_2 (2 \times 20 mL), and dry Et_2O (4 \times 20 mL), sequentially. The resulting white solid was dried under

vacuum and stored under argon in a flask covered with aluminum foil at $-10\text{ }^{\circ}\text{C}$.

One-Pot Lactam Reduction/Mannich/Michael Reaction: General Procedure. To a solution of $\text{Cp}_2\text{Zr}(\text{H})\text{Cl}$ (Schwartz's reagent; 1.6 equiv, 206 mg, 0.8 mmol) in THF (5 mL) was added a solution of the sugar lactam (0.5 mmol) in THF (5 mL). The initially formed white suspension disappeared during the reaction progress; formation of a clear solution indicated the end of the reaction (ca. 1.5 h, TLC monitoring). Then the solution was cooled to $-25\text{ }^{\circ}\text{C}$ and $\text{Yb}(\text{OTf})_3$ was added (10 mol%, 31 mg, 0.05 mmol). After 10 min neat diene (2.0 equiv 194 μL , 1.0 mmol) was added dropwise. The mixture was warmed gradually to room temperature and stirred for 2.5 h (TLC monitoring). The reaction was quenched with saturated aqueous NaHCO_3 (5 mL) and diluted with Et_2O (5 mL). The organic layer was separated, and the aqueous layer was washed with Et_2O (3×5 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and the solvent was removed. The residue was purified by chromatography on silica gel to give the corresponding enamine.

(*6R,7R,8R,9S,9aR*)-7,8,9-Tris(benzyloxy)-6-(benzyloxymethyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (**10** and **9a-epi-10**): for yield and de see Table 3; column chromatography (50% AcOEt in hexanes); major isomer **10** (pure sample obtained by preparative TLC, Merck preparative TLC plates Si60 F254, 20×20 cm, hexanes/AcOEt 2/1); colorless oil; $[\alpha]_{\text{D}} -49.3$ (c 0.3, CH_2Cl_2); $R_f = 0.24$ (50% AcOEt in hexanes); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.36–7.21 (m, 18H), 7.11–7.05 (m, J 6.6, 2.8 Hz, 2H), 7.01 (d, J 7.7 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.98 (d, J 7.7 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.60 (d, J 12.0 Hz, 1H, OCHHPh), 4.58–4.51 (m, 2H, OCH_2Ph), 4.45 (d, J 12.0 Hz, 1H, OCHHPh), 4.41–4.38 (m, 2H, OCH_2Ph), 4.31 (d, J 12.0 Hz, 1H, OCHHPh), 4.26 (d, J 12.0 Hz, 1H, OCHHPh), 3.80 (ddd, J 13.4, 6.2, 2.5 Hz, 1H, H-9a), 3.78–3.74 (m, J 8.0, 5.3, 1.6 Hz, 1H, H-6), 3.73–3.70 (m, J 3.0, 2.8 Hz, 1H, H-8), 3.70–3.67 (dd, J 10.0, 8.0 Hz, 1H, CHHOBn), 3.65–3.62 (m, J 3.0, 2.1 Hz, 1H, H-7), 3.52 (dd, J 10.0, 5.3 Hz, 1H, CHHOBn), 3.34–3.30 (m, J 2.8, 2.5 Hz, 1H, H-9), 3.02 (dd, J 16.4, 13.5 Hz, 1H, H-1'), 2.19 (dd, J 16.4, 6.2 Hz, 1H, H-1''); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 192.6, 155.3, 137.6, 137.5, 137.2, 137.1, 128.6, 128.5, 128.4, 128.1, 128.1, 123.0, 127.9, 127.8, 127.7, 98.7, 75.0, 73.3, 72.9, 72.7, 72.2, 72.0, 71.9, 67.5, 63.0, 51.3, 37.4; HRMS (ESI-TOF) m/z calcd for $\text{C}_{38}\text{H}_{39}\text{NO}_5\text{Na}$ [$\text{M} + \text{Na}^+$] 612.2721, found 612.2700; IR (film) ν 3433, 2923, 2863, 1637, 1586, 1454, 1092, 738, 698 cm^{-1} ; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 0.5 mL/min, UV 315 nm, R_t 19.8 min (**10** major isomer), 24.5 min (**9a-epi-10** minor isomer).

(*6R,7R,8R,9R,9aR*)-7,8,9-Tris(benzyloxy)-6-(benzyloxymethyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (**32** and **9a-epi-32**): mixture of diastereoisomers; isolated yield 107 mg (73%, both isomers) starting from 135 mg (0.25 mmol) of lactam **12**; $d.r.$ 94:6 (determined by HPLC of crude reaction mixture); $R_f = 0.34$ (3/2 AcOEt/hexanes); column chromatography (1/1 AcOEt/hexane); major isomer **32** (pure sample obtained by preparative TLC, Merck preparative TLC plates Si60 F254, 20×20 cm, hexanes/AcOEt 2/1); colorless oil; $[\alpha]_{\text{D}} -67.6$ (c 1.3, CH_2Cl_2); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.36–7.22 (m, 16H), 7.19–7.14 (m, 4H), 6.93 (d, J 7.7 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.98 (d, J 7.7 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.57 (d, J 12.0 Hz, 1H, OCHHPh), 4.48–4.37 (m, 6H, $3 \times \text{OCH}_2\text{Ph}$) 4.35 (d, J 12.2 Hz, 1H, OCHHPh), 3.91–3.87 (m, J 10.2, 8.2, 6.7 Hz, 1H, H-9a), 3.83–3.75 (m, 3H, H-6, H-8, H-9), 3.66 (d, J 3.7 Hz, 1H, H-7), 3.60–3.55 (m, 2H, CH_2OBn), 2.77 (dd, J 16.7, 6.7 Hz, 1H, H-1'), 2.60 (dd, J 16.7, 8.2 Hz, 1H, H-1''); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 155.4, 137.7, 137.5, 137.4, 128.6, 128.5, 128.4, 128.2, 128.0, 127.9, 127.9, 127.9, 127.7, 127.5, 98.7, 74.5, 74.3, 73.29, 73.25, 73.1, 72.5, 71.7, 67.9, 64.8, 51.5, 37.2; minor isomer **9a-epi-32** selected signals $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.85 (d, J 7.9 Hz, 1H); HRMS (ESI-TOF) m/z calcd for $\text{C}_{38}\text{H}_{39}\text{NO}_5\text{Na}$ [$\text{M} + \text{Na}^+$] 612.2721, found 612.2734; IR (film) ν 2924, 2866, 1640, 1588, 1453, 1100, 737, 698 cm^{-1} ; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 0.5 mL/min, UV 313 nm, R_t 14.4 min (**9a-epi-32** minor isomer), 15.8 min (**32** major isomer).

(*6R,7S,8R,9S,9aS*)-7,8,9-Tris(benzyloxy)-6-(benzyloxymethyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (**33** and **9a-epi-33**): inseparable mixture of diastereoisomers; colorless oil; isolated yield 120

mg (81%, both isomers) starting from 135 mg (0.25 mmol) of lactam **13**; $d.r.$ 90:10 (determined by $^1\text{H NMR}$ of crude reaction mixture); $R_f = 0.26$ (50% AcOEt in hexanes); column chromatography (50% AcOEt in hexanes); major isomer **33** $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.40–7.23 (m, 18H), 7.26–7.21 (m, 2H), 6.89 (d, J 7.8 Hz, 1H, $\text{CH}=\text{CHCO}$), 5.02 (d, J 7.7 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.91 (d, J 10.5 Hz, 1H, OCHHPh), 4.76 (d, J 12.3 Hz, 1H, OCHHPh), 4.66 (d, J 12.3 Hz, 1H, OCHHPh), 4.62 (d, J 10.5 Hz, 1H, OCHHPh), 4.60–4.58 (m, 2H, OCH_2Ph), 4.44 (s, 2H, OCH_2Ph), 3.97 (t, J 9.3 Hz, 1H, H-9), 3.89 (t, J 2.8 Hz, 1H, H-7), 3.68 (dt, J 6.2, 5.8, 2.8 Hz, 1H, H-6), 3.63 (dd, J 8.8, 2.7 Hz, 1H, H-8), 3.53–3.46 (m, 2H, CHHOBn, H-9a), 3.38 (dd, J 9.9, 5.8 Hz, 1H, CHHOBn), 2.82 (dd, J 16.5, 6.2 Hz, 1H, H-1') 2.62 (dd, J 16.5, 9.9 Hz, 1H, H-1''); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 191.2, 155.2, 137.9, 137.8, 137.2, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 127.9, 127.87, 127.8, 127.7, 99.3, 79.7, 77.6, 75.8, 73.6, 73.4, 72.4, 72.3, 67.5, 64.1, 56.2, 38.4; minor isomer **9a-epi-33** selected signals $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.13 (d, J 7.7 Hz, 1H), 5.00 (d, J 7.8 Hz, 1H); HRMS (ESI-TOF) m/z calcd for $\text{C}_{38}\text{H}_{39}\text{NO}_5\text{Na}$ [$\text{M} + \text{Na}^+$] 612.2721, found 612.2739; IR (film) ν 3443, 2923, 2867, 1638, 1587, 1453, 1095, 738, 698 cm^{-1} .

(*7R,8R,9R,9aR*)-7,8,9-Tris(benzyloxy)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (**34** and **9a-epi-34**): mixture of diastereoisomers; yield 78 mg (67%) starting from 100 mg (0.25 mmol) of lactam **14**; $d.r.$ 88:12; $R_f = 0.36$ (100% AcOEt); column chromatography (100% AcOEt); major isomer **34** (pure sample obtained by preparative TLC, Merck preparative TLC plates Si60 F254, 20×20 cm, hexanes/AcOEt 1/9); colorless oil; $[\alpha]_{\text{D}} -162.7$ (c 0.16, CH_2Cl_2); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.36–7.26 (m, 15H), 6.80 (d, J 7.6 Hz, 1H, $\text{CH}=\text{CHCO}$), 5.05 (d, J 7.6 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.96 (d, J 10.5 Hz, 1H, OCHHPh), 4.77 (d, J 12.4 Hz, 1H, OCHHPh), 4.68–4.62 (m, 4H, $2 \times \text{OCH}_2\text{Ph}$), 3.97 (ps t, J 9.9, 9.3 Hz, 1H, H-9), 3.86–3.83 (m, 1H, H-7), 3.49 (dd, J 9.3, 2.9 Hz, 1H, H-8), 3.40 (dd, J 13.9, 2.8 Hz, 1H, H-6'), 3.28 (dt, J 9.9, 7.2, 6.8 Hz, 1H, H-9a), 3.03 (d, J 13.9 Hz, 1H, H-6''), 2.83 (dd, J 16.8, 6.8 Hz, 1H, H-1'), 2.70 (dd, J 16.8, 7.2 Hz, 1H, H-1''); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 155.1, 137.9, 137.8, 137.7, 128.5, 128.4, 128.2, 127.9, 127.8, 127.65, 127.64, 99.1, 83.3, 76.2, 75.9, 72.6, 72.2, 72.1, 60.0, 54.7, 36.8; HRMS (ESI-TOF) m/z calcd for $\text{C}_{30}\text{H}_{31}\text{NO}_4\text{Na}$ [$\text{M} + \text{Na}^+$] 492.2145, found 492.2122; IR (film) ν 2900, 1623, 1574, 1455, 1383, 1200, 1173, 1125, 1105, 739, 718, 697 cm^{-1} ; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 0.5 mL/min, UV 304 nm, R_t 18.4 min (**9a-epi-34** minor isomer), 22.9 min (**34** major isomer).

(*1S,2R,3R,8aR*)-1,2-Bis(benzyloxy)-3-(benzyloxymethyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (**35**): isolated yield 72 mg (62%, both isomers) starting from 100 mg (0.25 mmol) of lactam **15**; $d.r.$ 96:4 (determined by HPLC of crude reaction mixture); column chromatography (100% AcOEt); pure sample of **35** obtained by preparative TLC (Merck preparative TLC plates Si60 F254, 20×20 cm, hexanes/AcOEt 1/9); colorless oil; $[\alpha]_{\text{D}} -181.4$ (c 1.1, CH_2Cl_2); $R_f = 0.28$ (100% AcOEt); $^1\text{H NMR}$ (600 MHz, 5% CDCl_3 in PhMe-d_7) δ 7.19–6.95 (m, 15H, $3 \times \text{Ph}$), 6.76 (d, J 7.3 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.98 (d, J 7.3 Hz, 1H, $\text{CH}=\text{CHCO}$), 4.48 (d, J 11.7 Hz, 1H, OCHHPh), 4.34 (d, J 11.7 Hz, 1H, OCHHPh), 4.30 (d, J 11.9 Hz, 1H, OCHHPh), 4.10–4.06 (m, 3H, $3 \times \text{OCH}_2\text{Ph}$), 3.59–3.55 (m, 2H, H-2, H-3), 3.40–3.36 (m, 1H, H-1), 3.33 (dt, J 16.4, 3.9 Hz, 1H, H-8a), 3.24 (dd, J 10.5, 1.6 Hz, 1H, CHHOBn), 3.15 (dd, J 10.5, 3.5 Hz, 1H, CHHOBn), 2.86 (t, J 16.4, 15.7 Hz, 1H, H-8_{anti}), 2.06 (dd, J 15.7, 4.7 Hz, 1H, H-8_{syn}); $^{13}\text{C NMR}$ (151 MHz, toluene- d_7) δ 189.8, 146.2, 137.1, 128.6, 128.5, 128.3, 128.2, 127.7, 127.5, 127.4, 124.9, 124.7, 124.6, 97.6, 79.6, 75.2, 67.2, 60.7, 60.0, 36.1, 20.4, 20.3, 20.1, 20.0, 19.9, 19.8, 19.6; HRMS (ESI-TOF) m/z calcd for $\text{C}_{30}\text{H}_{31}\text{NO}_4\text{Na}$ [$\text{M} + \text{Na}^+$] 492.2145, found 492.2126; IR (film) ν 2920, 2864, 1574, 1454, 1260, 1172, 1030, 738, 698, 638 cm^{-1} ; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 0.5 mL/min, UV 329 nm, R_t 22.3 min (**35** major isomer), 28.4 min (**8a-epi-35** minor isomer).

(*1S,2S,8aS*)-1,2-Bis(benzyloxy)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (**37** and **8a-epi-37**): inseparable mixture of diastereoisomers; colorless oil; yield 48 mg (55%) starting from 75 mg (0.25 mmol) of lactam **18**; $d.r.$ 90:10; $R_f = 0.22$ (100% AcOEt); column chromatography (100% AcOEt); major isomer **37** $^1\text{H NMR}$

(600 MHz, CDCl₃) δ 7.40–7.22 (m, 10H), 7.03 (d, *J* 7.2 Hz, 1H, CH=CHCO), 4.96 (d, *J* 7.2 Hz, 1H, CH=CHCO), 4.64–4.55 (m, 6H, OCH₂Ph), 4.14 (dt, *J* 5.9, 4.0 Hz, 1H, H-2), 3.95 (dd, *J* 5.8, 4.1 Hz, 1H, H-1), 3.81–3.75 (m, 1H, H-8a), 3.68 (dd, *J* 11.3, 6.1 Hz, 1H, H-3'), 3.45 (dd, *J* 11.3, 3.9 Hz, 1H, H-3''), 2.53–2.50 (m, 2H, H-8, H-8''); ¹³C NMR (151 MHz, CDCl₃) δ 191.4, 150.1, 137.3, 137.2, 128.59, 128.57, 128.11, 128.09, 127.74, 127.72, 98.3, 87.0, 82.0, 72.4, 72.1, 61.7, 53.4, 40.0; minor isomer **8a-epi-37** ¹H NMR (600 MHz, CDCl₃, selected signals) δ 4.06 (m, 1H, H-8a), 2.88 (ps t, *J* 16.7, 16.2, Hz, H-8_{anti}), 2.22 (dd, *J* 16.2, 4.8 Hz, 1H, H-8_{syn}); HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₄NO₃ [M + H⁺] 350.1756, found 350.1716; IR (film) ν 3031, 2923, 2868, 1634, 1580, 1454, 1359, 1353, 1250, 1096, 738, 698 cm⁻¹; HPLC LiChrosphere Si60, 40% *i*-PrOH in hexanes, flow 1.0 mL/min, UV 329 nm, R_t 9.8 min (**8a-epi-37** minor isomer); 12.1 min (37 major isomer).

(1*S*,2*R*,8*aS*)-1,2-Bis(benzyloxy)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**38** and **8a-epi-38**): inseparable mixture of diastereoisomers; colorless oil; isolated yield 55 mg (63%, both isomers) starting from 75 mg (0.25 mmol) of lactam **19**; *d.r.* 86:14 (determined by HPLC of crude reaction mixture); R_f = 0.27 (100% AcOEt); column chromatography (100% AcOEt); major isomer **38** ¹H NMR (600 MHz, C₆D₆) δ 7.17–7.09 (m, 7H), 7.09–7.03 (m, 3H), 6.19 (d, *J* 7.3 Hz, 1H, CH=CHCO), 5.08 (d, *J* 7.3 Hz, 1H, CH=CHCO), 4.26–4.23 (m, 2H, OCH₂Ph), 4.16 (d, *J* 12.0 Hz, 1H, OCHHPh), 4.11 (d, *J* 12.0 Hz, 1H, OCHHPh), 3.62 (dt, *J* 6.3, 4.5 Hz, 1H, H-2), 3.58 (dd, *J* 6.4, 4.5 Hz, 1H, H-1), 3.43–3.37 (ps dt, *J* 16.2, 6.4, 4.8 Hz, 1H, H-8a), 2.78 (dd, *J* 11.0, 6.3 Hz, 1H, H-3'), 2.70 (dd, *J* 11.0, 4.4 Hz, 1H, H-3''), 2.50 (dd, *J* 15.6, 4.8 Hz, 1H, H-8'), 2.28 (ps t, *J* 16.2, 15.6 Hz, 1H, H-8''); ¹³C NMR (151 MHz, C₆D₆) δ 189.4, 148.5, 137.91, 137.90, 128.32, 128.25, 127.7, 127.5, 127.4, 98.7, 87.0, 81.8, 71.8, 71.4, 61.2, 52.4, 40.5; minor isomer **8a-epi-38** selected signals ¹H NMR (600 MHz, C₆D₆) δ 6.38 (d, *J* 7.2 Hz, 1H, CH=CHCO), 5.12 (d, *J* 7.2 Hz, 1H, CH=CHCO), 3.73 (dt, *J* 16.9, 4.7, 3.2 Hz, H-8a), 3.46 (d, *J* 3.2 Hz, H-1), 3.07 (dd, *J* 11.6, 4.8 Hz, H-3'), 2.87 (ps t, *J* 16.9, 15.6 Hz, H-8'), 2.23 (dd, *J* 15.6, 4.7 Hz, H-8''); ¹³C NMR (151 MHz, C₆D₆) δ 190.3, 148.1, 97.7, 80.6, 79.4, 71.9, 70.8, 59.2, 52.7, 35.7; HRMS (ESI-TOF) *m/z* calcd for C₂₂H₂₄NO₃ [M + H⁺] 350.1756, found 350.1750; IR (film) ν 3030, 2868, 1634, 1578, 1455, 1356, 1335, 1250, 1095, 739, 698 cm⁻¹; HPLC Chiralpak AD-H, 40% *i*-PrOH in hexanes, flow 1.0 mL/min, UV 340 nm, R_t 10.2 min (**8a-epi-38** minor isomer), 12.8 min (**38** major isomer).

(2*R*,8*aR*)-2-(Benzyloxy)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**39** and **8a-epi-39**): inseparable mixture of diastereoisomers; colorless oil; isolated yield 79 mg (63%, both isomers) starting from 100 mg (0.52 mmol) of lactam **20**; *d.r.* 80:20 (determined by ¹H NMR of crude reaction mixture); R_f = 0.33 (3/2 acetone/hexanes); column chromatography (100% AcOEt); major isomer **39** ¹H NMR (600 MHz, C₆D₆) δ 7.15–7.07 (m, 5H), 6.22 (d, *J* 7.3 Hz, 1H, CH=CHCO), 5.10 (d, *J* 7.3 Hz, 1H, CH=CHCO), 4.08 (d, *J* 12.1 Hz, 1H, OCHHPh), 3.99 (d, *J* 12.1 Hz, 1H, OCHHPh), 3.40 (dt, *J* 13.2, 6.6 Hz, 1H, H-2), 3.03 (m, 1H, H-8a), 2.73 (dd, *J* 10.6, 5.7 Hz, 1H, H-3'), 2.61 (dd, *J* 10.6, 6.9 Hz, 1H, H-3''), 2.24 (dd, *J* 15.6, 4.6 Hz, 1H, H-8'), 2.13 (t, *J* 15.7 Hz, H-8''), 1.62 (dt, *J* 12.3, 6.3 Hz, 1H, H-1'), 1.20 (ddd, *J* 12.3, 10.1, 7.6 Hz, 1H, H-1''); ¹³C NMR (151 MHz, C₆D₆) δ 190.0, 148.1, 138.1, 128.3–127.3 (Ar), 98.5, 76.3, 71.1, 56.1, 53.7, 41.9, 38.0; minor isomer **8a-epi-39** selected signals ¹H NMR (600 MHz, C₆D₆) δ 6.31 (d, *J* 7.3 Hz, 1H, CH=CHCO), 5.14 (d, *J* 7.2 Hz, 1H, CH=CHCO), 2.66 (dd, *J* 11.6, 5.0 Hz, 1H, H-3'), 2.31 (dd, *J* 15.6, 4.6 Hz, H-8'); 1.98 (ps t, *J* 16.2, 15.5 Hz, 1H, H-8''); HRMS (ESI-TOF) *m/z* calcd for C₁₅H₁₈NO₂ [M + H⁺] 244.1338, found 244.1339; IR (film) ν 3253, 2926, 2870, 1699, 1632, 1577, 1455, 1330, 1251, 1096, 742, 699 cm⁻¹.

(1*R*,8*aS*)-1-(Benzyloxy)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**40**): colorless oil; isolated yield 54 mg (43%) starting from 100 mg (0.52 mmol) of lactam **21**; [α]_D –241.5 (c 3.3, CHCl₃); R_f = 0.43 (100% acetone); column chromatography (35% acetone in hexanes); ¹H NMR (600 MHz, C₆D₆) δ 7.14–7.04 (m, 5H), 6.21 (d, *J* 7.2 Hz, 1H, CH=CHCO), 5.07 (d, *J* 7.2 Hz, 1H, CH=CHCO), 4.08–4.07 (m, 2H, OCH₂Ph), 3.38 (dt, *J* 16.3, 6.3, 4.8 Hz, 1H, H-8a), 3.24 (m, H-1), 2.64–2.59 (m, 1H, H-3'), 2.54 (dd, *J* 15.6, 4.8 Hz, 1H, H-8'),

2.42 (dt, *J* 10.0, 7.6 Hz, 1H, H-3''), 2.07 (ps t, *J* 16.2, 15.6 Hz, 1H, H-8'), 1.51–1.48 (m, 1H, H-2'), 1.33–1.27 (m, 1H, H-2''); ¹³C NMR (151 MHz, C₆D₆) δ 189.5, 148.4, 138.1, 128.2, 127.5, 127.3, 98.0, 82.6, 71.2, 62.0, 46.6, 40.5, 30.5; HRMS (ESI-TOF) *m/z* calcd for C₁₅H₁₈NO₂ [M + H⁺] 244.1338, found 244.1337; IR (film) ν 3437, 2877, 1633, 1576, 1456, 1361, 1248, 1110, 742, 699 cm⁻¹.

(1*R*,8*aR*)-1-(Benzyloxy)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**8a-epi-40**): colorless oil; isolated yield 10 mg (8%) starting from 100 mg (0.52 mmol) of lactam **21**; [α]_D +276.7 (c 0.5, CHCl₃); R_f = 0.38 (100% acetone); column chromatography (35% acetone in hexanes); ¹H NMR (600 MHz, C₆D₆) δ 7.13–7.01 (m, 5H), 6.33 (d, *J* 7.2 Hz, 1H, CH=CHCO), 5.14 (d, *J* 7.2 Hz, 1H, CH=CHCO), 4.05 (d, *J* 12.1 Hz, 1H, OCHHPh), 3.95 (d, *J* 12.1 Hz, 1H, OCHHPh), 3.20 (ps t, *J* 3.9, 3.7 Hz, 1H, H-1), 3.11 (dt, *J* 16.0, 4.6, 3.9 Hz, 1H, H-8a), 2.88 (ps t, *J* 16.0, 15.6 Hz, 1H, H-8'), 2.85–2.80 (m, 1H, H-3'), 2.41 (t, *J* 9.4 Hz, 1H, H-3''), 2.23 (dd, *J* 15.6, 4.6 Hz, 1H, H-8'), 1.41 (dd, *J* 13.5, 7.0 Hz, 1H, H-2'), 1.31–1.25 (m, 1H); ¹³C NMR (151 MHz, C₆D₆) δ 190.5, 147.9, 138.1, 128.2, 127.9–127.4 (Ar), 127.2, 97.4, 78.0, 70.9, 61.2, 46.3, 36.2, 29.4; HRMS (ESI-TOF) *m/z* calcd for C₁₅H₁₈NO₂ [M + H⁺] 244.1338, found 244.1339; IR (film) ν 3434, 2921, 1625, 1573, 1455, 1356, 1256, 1172, 1115, 1064, 1030, 742, 699 cm⁻¹.

(2*S*,3*R*,8*aS*)-2-(Benzyloxy)-3-(benzyloxymethyl)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**36** and **8a-epi-36**): mixture of diastereoisomers; isolated yield 70 mg (61%, both isomers) starting from 100 (0.32 mmol) of lactam **17**; *d.r.* 87:13 (determined by ¹H NMR of crude reaction mixture); R_f = 0.26 (100% AcOEt); column chromatography (100% AcOEt); major isomer **36** (pure sample obtained by preparative TLC, Merck preparative TLC plates Si60 F254, 20 × 20 cm, hexanes/AcOEt 1/8); yellow oil; [α]_D –141.3 (c 0.6, CHCl₃); ¹H NMR (500 MHz, C₆D₆) δ 7.15–7.04 (m, 10H), 6.72 (d, *J* 7.1 Hz, 1H, CH=CHCO), 5.18 (d, *J* 7.0 Hz, 1H, CH=CHCO), 4.15 (d, *J* 12.0 Hz, 1H, OCHHPh), 4.09–4.06 (m, 2H, OCH₂Ph), 4.04 (d, *J* 12.0 Hz, 1H, OCHHPh), 3.58–3.53 (m, 1H, H-2), 3.37–3.28 (m, 2H, H-3, H-8a), 3.01 (dd, *J* 10.3, 3.8 Hz, 1H, H-3'), 2.96 (dd, *J* 10.3, 5.5 Hz, 1H, H-3''), 2.27 (dd, *J* 15.6, 4.8 Hz, 1H, H-8'), 2.19 (t, *J* 15.6 Hz, 1H, H-8''), 1.68 (dt, *J* 12.3, 6.3 Hz, 1H, H-1'), 1.24–1.15 (m, 1H, H-1''); ¹³C NMR (126 MHz, C₆D₆) δ 189.7, 147.1, 138.1, 137.7, 128.3, 128.2, 127.9, 127.7, 127.5, 127.3, 98.4, 78.9, 72.9, 71.1, 69.3, 64.7, 56.5, 42.2, 37.3; minor isomer **8a-epi-36** selected signals ¹H NMR (500 MHz, C₆D₆) δ 6.61 (d, *J* 7.4 Hz, 1H, CH=CHCO), 5.20 (d, *J* 7.4 Hz, 1H, CH=CHCO); HRMS (ESI-TOF) *m/z* calcd for C₂₃H₂₆NO₃ [M + H⁺] 364.1913, found 364.1910; IR (film) ν 3475, 2924, 2862, 1632, 1572, 1455, 1285, 1096, 1031, 740, 699, 638 cm⁻¹.

(3*S*)-3-((*tert*-Butyldiphenylsilyloxy)methyl)-2,3,8*a*-tetrahydroindolizin-7(1*H*)-one (**41** and **8a-epi-41**): inseparable mixture of diastereoisomers; colorless oil; isolated yield 57 mg (55%, both isomers) starting from 90 mg (0.25 mmol) of lactam **22**; *d.r.* 82:18 (determined by HPLC of crude reaction mixture); R_f = 0.44 (100% AcOEt); column chromatography (100% Et₂O then 100% AcOEt); major isomer **41** ¹H NMR (600 MHz, CDCl₃) δ 7.68–7.57 (m, 5H), 7.47–7.36 (m, 5H), 7.34 (d, *J* 7.2 Hz, 1H, CH=CHCO), 4.93 (d, *J* 7.2 Hz, 1H, CH=CHCO), 3.86 (ddd, *J* 15.6, 10.7, 5.6 Hz, 1H, H-8a), 3.82–3.78 (m, 1H, H-3), 3.69 (dd, *J* 11.0, 3.5 Hz, 1H, CHHOSi), 3.61 (dd, *J* 11.0, 5.8 Hz, 1H, CHHOSi), 2.43 (dd, *J* 15.9, 6.1 Hz, 1H, H-8'), 2.36 (t, *J* 15.9 Hz, 1H, H-8''), 2.23–2.19 (m, 1H, H-1'), 2.15–2.09 (m, 1H, H-2'), 1.79–1.72 (m, 1H, H-2''), 1.67–1.62 (m, 1H, H-1''), 1.04 (s, 9H, *t*-Bu); ¹³C NMR (151 MHz, CDCl₃) δ 191.8, 149.5, 135.6, 135.5, 132.7, 132.6, 130.0, 129.89, 127.85, 127.84, 127.81, 96.9, 65.1, 61.5, 58.5, 41.8, 31.7, 27.0, 26.8, 19.1; minor isomer **8a-epi-41** selected signals ¹H NMR (600 MHz, CDCl₃) δ 4.99 (d, *J* 7.1 Hz, 1H), 3.48 (dd, *J* 10.4, 7.4 Hz, 1H), 2.01–1.95 (m, 2H), 1.82 (dd, *J* 13.1, 7.1 Hz, 1H); HRMS (ESI-TOF) *m/z* calcd for C₂₅H₃₁NO₂NaSi [M + Na⁺] 428.20347, found 428.2035; IR (film) ν 2958, 2931, 2857, 1635, 1574, 1427, 1252, 1112, 703, 504 cm⁻¹; HPLC Chiralpak AD-H, 20% *i*-PrOH in hexanes, flow 1.0 mL/min, UV 327 nm, R_t 8.9 min (minor isomer **8a-epi-41**), 10.4 min (major isomer **41**).

(6*R*,7*R*,8*R*,9*S*,9*aR*)-7,8,9-Tris(benzyloxy)-6-(benzyloxymethyl)-hexahydro-1*H*-quinolizin-2(6*H*)-one (**11**). To a solution of **10** (58 mg, 0.1 mmol) in dry THF (5 mL) was added a 1 M solution of L-

Selectride in THF (1.3 equiv, 0.13 mmol) dropwise at $-25\text{ }^{\circ}\text{C}$. The mixture was stirred for 25 min at $-25\text{ }^{\circ}\text{C}$. The reaction progress was monitored by TLC (1/1 AcOEt/hexanes). Then the mixture was warmed gradually to $0\text{ }^{\circ}\text{C}$ and was quenched with saturated aqueous NH_4Cl (5 mL). The organic layer was separated, and the aqueous layer was washed with Et_2O ($3 \times 5\text{ mL}$). The combined organic layers were dried over anhydrous Na_2SO_4 , and the solvent was removed. The residue was chromatographed on silica gel (1/4 AcOEt/hexanes) to give 36 mg of **11** as a white solid: isolated yield 63%; mp $107\text{--}108\text{ }^{\circ}\text{C}$; $[\alpha]_{\text{D}} +19.0$ ($c\ 1.0$, CHCl_3); $R_f = 0.54$ (1/1 AcOEt/hexanes); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.35–7.23 (m, 18H), 7.12 (d, $J\ 7.5\text{ Hz}$, 2H), 4.89 (dd, $J\ 10.7, 3.6\text{ Hz}$, 2H), 4.77 (d, $J\ 10.8\text{ Hz}$, 1H), 4.64–4.60 (m, 2H), 4.54–4.44 (m, 3H), 4.40 (d, $J\ 10.8\text{ Hz}$, 1H), 3.83 (dd, $J\ 9.3, 5.6\text{ Hz}$, 1H), 3.75–3.67 (m, 2H), 3.64 (d, $J\ 10.1\text{ Hz}$, 1H), 3.62–3.54 (m, 2H), 3.51 (dd, $J\ 13.5, 7.6\text{ Hz}$, 1H), 3.02 (d, $J\ 9.1\text{ Hz}$, 1H), 2.96 (t, $J\ 12.9\text{ Hz}$, 1H), 2.51 (d, $J\ 8.0\text{ Hz}$, 2H), 2.14 (d, $J\ 14.6\text{ Hz}$, 1H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 208.3, 138.5, 138.1, 137.9, 137.5, 128.5, 128.40, 128.36, 128.2, 128.0, 127.92, 127.85, 127.8, 127.7, 127.6, 82.4, 78.6, 78.4, 75.5, 75.3, 73.6, 72.7, 66.3, 60.1, 56.1, 48.8, 37.5, 37.1; HRMS (ESI-TOF) m/z calcd for $\text{C}_{11}\text{H}_{13}\text{NO}_2\text{Na}$ [$\text{M} + \text{Na}^+$] 214.0844, found 214.0842; IR (film) ν 3236, 2916, 1693, 1667, 1354, 1095, 728 cm^{-1} . Absolute configuration was confirmed by X-ray analysis.⁶⁴

■ ASSOCIATED CONTENT

📄 Supporting Information

Figures, tables, and a CIF file giving ^1H and ^{13}C NMR spectra, stereochemical proofs, HPLC data for selected compounds, and X-ray crystallographic data for compound **11**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail for S.S.: sebastian.stecko@icho.edu.pl.

*E-mail for B.F.: bartlomiej.furman@icho.edu.pl.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support by the European Union within the European Regional Development Fund, Project POIG.01.01.02.-14-102/09, is gratefully acknowledged. The authors are also grateful for The Regional Council of Mazovia and European Union within the European Regional Development Fund for a Ph.D. student scholarship (P.S.).

■ REFERENCES

- (1) (a) Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. *Phytochemistry* **2001**, *56*, 265–295. (b) Stütz, A. E. *Iminosugars as Glycosidase Inhibitors*; Wiley-VCH: Weinheim, Germany, 2004. (c) Compain, P.; Martin, O. R. *Iminosugars: From Synthesis to Therapeutic Applications*. Wiley-VCH: Weinheim, Germany, 2007.
- (2) (a) Ayad, T.; Genisson, Y.; Baltas, M. *Curr. Org. Chem.* **2004**, *8*, 1211–1233. (b) Kim, I. S. J.; Y, H. *Heterocycles* **2011**, *83*, 2489–2507. (c) Cardona, F.; Goti, A.; Brandi, A. *Eur. J. Org. Chem.* **2007**, 2007, 1551–1565. (d) El Nemr, A. *Tetrahedron* **2000**, *56*, 8579–8629. (e) Pyne, S. G. *Curr. Org. Synth.* **2005**, *2*, 39–57.
- (3) Ashry, E. S. H. E. *Heterocycles from Carbohydrate Precursors*; Springer: Berlin, 2007.
- (4) Ashry, E. S. H. E.; Nemr, A. E. *Synthesis of Naturally Occurring Nitrogen Heterocycles from Carbohydrates*. Wiley: Hoboken, NJ, 2008.
- (5) (a) Liddell, J. R. *Nat. Prod. Rep.* **1998**, *15*, 363–370. (b) Liddell, J. R. *Nat. Prod. Rep.* **1999**, *16*, 499–507. (c) Liddell, J. R. *Nat. Prod. Rep.* **2000**, *17*, 455–462. (d) Liddell, J. R. *Nat. Prod. Rep.* **2001**, *18*, 441–447. (e) Liddell, J. R. *Nat. Prod. Rep.* **2002**, *19*, 773–781.

- (6) (a) Michael, J. P. *Nat. Prod. Rep.* **1997**, *14*, 619–636. (b) Michael, J. P. *Nat. Prod. Rep.* **1997**, *14*, 21–41. (c) Michael, J. P. *Nat. Prod. Rep.* **1998**, *15*, 571–594. (d) Michael, J. P. *Nat. Prod. Rep.* **1999**, *16*, 675–696. (e) Michael, J. P. *Nat. Prod. Rep.* **2000**, *17*, 579–602. (f) Michael, J. P. *Nat. Prod. Rep.* **2001**, *18*, 520–542. (g) Michael, J. P. *Nat. Prod. Rep.* **2002**, *19*, 719–741. (h) Michael, J. P. *Nat. Prod. Rep.* **2003**, *20*, 458–475. (i) Michael, J. P. *Nat. Prod. Rep.* **2004**, *21*, 625–649. (j) Michael, J. P. *Nat. Prod. Rep.* **2005**, *22*, 603–626. (k) Michael, J. P. *Nat. Prod. Rep.* **2007**, *24*, 191–222. (l) Michael, J. P. *Nat. Prod. Rep.* **2008**, *25*, 139–165.

(7) Lahiri, R.; Ansari, A. A.; Vankar, Y. D. *Chem. Soc. Rev.* **2013**, *42*, 5102–5118.

(8) Merino, P.; Tejero, T. *Molecules* **1999**, *4*, 169–179.

(9) Padwa, A. *1,3-Dipolar Cycloaddition Chemistry*; Wiley: New York, 1984.

(10) Gothelf, K. V.; Jørgensen, K. A. *Chem. Rev.* **1998**, *98*, 863–909.

(11) Padwa, A., In *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products*; Padwa, A., Pearson, W. H., Eds.; Wiley: Hoboken, NJ, 2003.

(12) Stecko, S.; Pieczykolan, M.; Ulkowski, A.; Kabala, K.; Wolosewicz, K.; Maciejko, M.; Grzeszczyk, B.; Jurczak, M.; Chmielewski, M.; Furman, B. *Curr. Org. Chem.* **2014**, *18*, 1716–1730.

(13) (a) Tufariello, J. J.; Tette, J. P. *J. Org. Chem.* **1975**, *40*, 3866–3869. (b) Tufariello, J. J. *Acc. Chem. Res.* **1979**, *12*, 396–403.

(c) Tufariello, J. J.; Asrof Ali, S. *J. Am. Chem. Soc.* **1979**, *101*, 7114–7116. (d) Tufariello, J. J.; Meckler, H.; Winzenberg, K. *J. Org. Chem.* **1986**, *51*, 3556–3557.

(14) (a) Cordero, F. M.; Brandi, A.; Querci, C.; Goti, A.; De Sarlo, F.; Guarna, A. *J. Org. Chem.* **1990**, *55*, 1762–1767. (b) Cicchi, S.; Hold, I.; Brandi, A. *J. Org. Chem.* **1993**, *58*, 5274–5275. (c) Brandi, A.; Cicchi, S.; Goti, A.; Koprowski, M.; Pietrusiewicz, K. M. *J. Org. Chem.* **1994**, *59*, 1315–1318. (d) Cicchi, S.; Goti, A.; Brandi, A. *J. Org. Chem.* **1995**, *60*, 4743–4748. (e) Goti, A.; Cicchi, S.; Fedi, V.; Nannelli, L.; Brandi, A. *J. Org. Chem.* **1997**, *62*, 3119–3125. (f) Cardona, F.; Valenza, S.; Picasso, S.; Goti, A.; Brandi, A. *J. Org. Chem.* **1998**, *63*, 7311–7318. (g) Cordero, F. M.; Gensini, M.; Goti, A.; Brandi, A. *Org. Lett.* **2000**, *2*, 2475–2477. (h) Goti, A.; Cacciarini, M.; Cardona, F.; Cordero, F. M.; Brandi, A. *Org. Lett.* **2001**, *3*, 1367–1369. (i) Cardona, F.; Goti, A.; Brandi, A. *Org. Lett.* **2003**, *5*, 1475–1478. (j) Cordero, F. M.; Pisaneschi, F.; Meschini Batista, K.; Valenza, S.; Machetti, F.; Brandi, A. *J. Org. Chem.* **2005**, *70*, 856–867. (k) Revuelta, J.; Cicchi, S.; Faggi, C.; Kozhushkov, S. I.; de Meijere, A.; Brandi, A. *J. Org. Chem.* **2006**, *71*, 2417–2423. (l) Cardona, F.; Lalli, D.; Faggi, C.; Goti, A.; Brandi, A. *J. Org. Chem.* **2008**, *73*, 1999–2002.

(15) Bernet, B.; Krawczyk, E.; Vasella, A. *Helv. Chim. Acta* **1985**, *68*, 2299–2311.

(16) (a) Carmona, A. T.; Whightman, R. H.; Robina, I.; Vogel, P. *Helv. Chim. Acta* **2003**, *86*, 3066–3073. (b) Cicchi, S.; Marradi, M.; Vogel, P.; Goti, A. *J. Org. Chem.* **2006**, *71*, 1614–1619.

(17) (a) Socha, D.; Jurczak, M.; Chmielewski, M. *Carbohydr. Res.* **2001**, *336*, 315–318. (b) Socha, D.; Pańniczek, K.; Jurczak, M.; Solecka, J.; Chmielewski, M. *Carbohydr. Res.* **2006**, *341*, 2005–2011. (c) Stecko, S.; Pańniczek, K.; Jurczak, M.; Urbańczyk-Lipkowska, Z.; Chmielewski, M. *Tetrahedron: Asymmetry* **2006**, *17*, 68–78. (d) Stecko, S.; Pańniczek, K.; Jurczak, M.; Urbańczyk-Lipkowska, Z.; Chmielewski, M. *Tetrahedron: Asymmetry* **2007**, *18*, 1085–1093. (e) Stecko, S.; Jurczak, M.; Urbańczyk-Lipkowska, Z.; Solecka, J.; Chmielewski, M. *Carbohydr. Res.* **2008**, *343*, 2215–2220. (f) Stecko, S.; Pańniczek, K.; Michel, C.; Milet, A.; Perez, S.; Chmielewski, M. *Tetrahedron: Asymmetry* **2008**, *19*, 2140–2148. (g) Stecko, S.; Jurczak, M.; Staszewska-Krajewska, O.; Solecka, J.; Chmielewski, M. *Tetrahedron* **2009**, *65*, 7056–7063. (h) Stecko, S.; Solecka, J.; Chmielewski, M. *Carbohydr. Res.* **2009**, *344*, 167–176. (i) Śnieżek, M.; Stecko, S.; Panfil, I.; Furman, B.; Urbańczyk-Lipkowska, Z.; Chmielewski, M. *Tetrahedron: Asymmetry* **2013**, *24*, 89–103.

(18) (a) Masson, G.; Lalli, C.; Benohoud, M.; Dagousset, G. *Chem. Soc. Rev.* **2013**, *42*, 902–923. (b) Buonora, P.; Olsen, J.-C.; Oh, T. *Tetrahedron* **2001**, *57*, 6099–6138. (c) Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2000**, *39*, 3558–3588. (d) Kobayashi, S.; Ishitani, H. *Chem.*

- Rev. **1999**, *99*, 1069–1094. (e) Rowland, G. B.; Rowland, E. B.; Zhang, Q.; Antilla, J. C. *Curr. Org. Chem.* **2006**, *10*, 981–1005.
- (19) Furman, B.; Dziedzic, M. *Tetrahedron Lett.* **2003**, *44*, 8249–8252.
- (20) (a) Dziedzic, M.; Małacka, M.; Furman, B. *Org. Lett.* **2005**, *7*, 1725–1727. (b) Furman, B.; Lipner, G. *Tetrahedron* **2008**, *64*, 3464–3470.
- (21) (a) Furman, B.; Dziedzic, M. *Tetrahedron Lett.* **2003**, *44*, 6629–6632. (b) Dziedzic, M.; Lipner, G.; Illangua, J. M.; Furman, B. *Tetrahedron* **2005**, *61*, 8641–8647.
- (22) Heintzelman, G. R.; Meigh, I. R.; Mahajan, Y. R.; Weinreb, S. M. *Org. React.* **2005**, *65*, 141–599.
- (23) Rowland, G. B.; Rowland, E. B.; Zhang, Q.; Antilla, J. C. *Curr. Org. Chem.* **2006**, *10*, 981–1025.
- (24) Pfrengle, W.; Kunz, H. *J. Org. Chem.* **1989**, *54*, 4261–4263.
- (25) Kunz, H.; Pfrengle, W. *Angew. Chem., Int. Ed.* **1989**, *28*, 1067–1068.
- (26) Weymann, M.; Pfrengle, W.; Schollmeyer, D.; Kunz, H. *Synthesis* **1997**, 1151–1160.
- (27) Vacca, J. P. *Tetrahedron Lett.* **1985**, *26*, 1277–1280.
- (28) (a) Danishefsky, S.; Langer, M. E.; Vogel, C. *Tetrahedron Lett.* **1985**, *26*, 5983–5986. (b) Danishefsky, S. J.; Vogel, C. *J. Org. Chem.* **1986**, *51*, 3915–3916.
- (29) (a) Han, G.; LaPorte, M. G.; Folmer, J. J.; Werner, K. M.; Weinreb, S. M. *J. Org. Chem.* **2000**, *65*, 6293–6306. (b) Han, G.; LaPorte, M. G.; Folmer, J. J.; Werner, K. M.; Weinreb, S. M. *Angew. Chem., Int. Ed.* **2000**, *39*, 237–240.
- (30) (a) Arnold, M. A.; Durón, S. G.; Gin, D. Y. *J. Am. Chem. Soc.* **2005**, *127*, 6924–6925. (b) Arnold, M. A.; Day, K. A.; Durón, S. G.; Gin, D. Y. *J. Am. Chem. Soc.* **2006**, *128*, 13255–13260.
- (31) Shao, J.; Yang, J.-S. *J. Org. Chem.* **2012**, *77*, 7891–7900.
- (32) (a) Davis, B. G.; Maughan, M. A. T.; Chapman, T. M.; Villard, R.; Courtney, S. *Org. Lett.* **2002**, *4*, 103–106. (b) Chapman, T. M.; Courtney, S.; Hay, P.; Davis, B. G. *Chem. Eur. J.* **2003**, *9*, 3397–3414. (c) Maughan, M. A. T.; Davies, I. G.; Claridge, T. D. W.; Courtney, S.; Hay, P.; Davis, B. G. *Angew. Chem., Int. Ed.* **2003**, *42*, 3788–3792. (d) Mayer, A.; Leumann, C. J. *Eur. J. Org. Chem.* **2007**, 4038–4049.
- (33) Stecko, S.; Jurczak, M.; Panfil, I.; Furman, B.; Grzeszczyk, B.; Chmielewski, M. *C. R. Chim.* **2011**, *14*, 102–125.
- (34) Desvergnès, S.; Py, S.; Vallée, Y. *J. Org. Chem.* **2005**, *70*, 1459–1462.
- (35) Yu, C.-Y.; Huang, M.-H. *Org. Lett.* **2006**, *8*, 3021–3024.
- (36) Maciejko, M.; Stecko, S.; Staszewska-Krajewska, O.; Jurczak, M.; Furman, B.; Chmielewski, M. *Synthesis* **2012**, *44*, 2825–2839.
- (37) Cividino, P.; Dheu-Andries, M.-L.; Ou, J.; Milet, A.; Py, S.; Toy, P. H. *Tetrahedron Lett.* **2009**, *50*, 7038–7042.
- (38) (a) Grigor'ev, I. A. Nitrones: Novel Strategies in Synthesis. In *Nitrile Oxides, Nitrones, and Nitronates in Organic Synthesis*; Wiley: Hoboken, NJ, 2007; pp 129–434. (b) Feuer, H. *Nitrile Oxides, Nitrones and Nitronates in Organic Synthesis: Novel Strategies in Synthesis*, 2nd ed.; Wiley: Weinheim, Germany, 2008. (c) Brandi, A.; Cardona, F.; Cicchi, S.; Cordero, F. M.; Goti, A. *Chem. Eur. J.* **2009**, *15*, 7808–7821.
- (39) Szcześniak, P.; Stecko, S.; Staszewska-Krajewska, O.; Furman, B. *Tetrahedron* **2014**, *70*, 1880–1888.
- (40) For reduction of amides to imines with Schwartz's reagent see: Schedler, D. J. A.; Li, J.; Ganem, B. *J. Org. Chem.* **1996**, *61*, 4115–4119.
- (41) (a) Barbe, G.; Charette, A. B. *J. Am. Chem. Soc.* **2007**, *130*, 18–19. (b) Pelletier, G.; Bechara, W. S.; Charette, A. B. *J. Am. Chem. Soc.* **2010**, *132*, 12817–12819. (c) Bechara, W. S.; Pelletier, G.; Charette, A. B. *Nat. Chem.* **2012**, *4*, 228–234. (d) Xiang, S.-H.; Xu, J.; Yuan, H.-Q.; Huang, P.-Q. *Synlett* **2010**, 1829–1832. (e) Xiao, K.-J.; Luo, J.-M.; Ye, K.-Y.; Wang, Y.; Huang, P.-Q. *Angew. Chem., Int. Ed.* **2010**, *49*, 3037–3040. (f) Xiao, K.-J.; Wang, Y.; Ye, K.-Y.; Huang, P.-Q. *Chem. Eur. J.* **2010**, *16*, 12792–12796.
- (42) Hoos, R.; Naughton, A. B.; Vasella, A. *Helv. Chim. Acta* **1992**, *75*, 1802–1807.
- (43) Overkleeft, H. S.; van Wiltenburg, J.; Pandit, U. K. *Tetrahedron* **1994**, *50*, 4215–4224.
- (44) Thaharn, W.; Bootwicha, T.; Soorukram, D.; Kuhakarn, C.; Prabpai, S.; Kongsaree, P.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Org. Chem.* **2012**, *77*, 8465–8479.
- (45) Cossy, J.; Cases, M.; Gomez Pardo, D. *Tetrahedron* **1999**, *55*, 6153–6166.
- (46) (a) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Woerpel, K. A. *J. Am. Chem. Soc.* **1999**, *121*, 12208–12209. (b) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **1999**, *122*, 168–169. (c) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125*, 15521–15528. (d) Smith, D. M.; Tran, M. B.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125*, 14149–14152. (e) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Smith, D. M.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127*, 10879–10884. (f) Lucero, C. G.; Woerpel, K. A. *J. Org. Chem.* **2006**, *71*, 2641–2647. (g) Yang, M. T.; Woerpel, K. A. *J. Org. Chem.* **2008**, *74*, 545–553. (h) Tran, V. T.; Woerpel, K. A. *J. Org. Chem.* **2013**, *78*, 6609–6621.
- (47) Renaud, P.; Seebach, D. *Helv. Chim. Acta* **1986**, *69*, 1704–1710.
- (48) Barker, R.; Fletcher, H. G. *J. Org. Chem.* **1961**, *26*, 4605–4609.
- (49) Ohno, K.; Yoshida, H.; Watanabe, H.; Fujita, T.; Matsuura, H. *J. Phys. Chem.* **1994**, *98*, 6924–6930.
- (50) (a) Stevens, R. V.; Lee, A. W. M. *J. Am. Chem. Soc.* **1979**, *101*, 7032–7035. (b) Deslongchamps, P. *Stereoelectronic Effects in Organic Chemistry*; Pergamon: New York, 1983. (c) Stevens, R. V. *Acc. Chem. Res.* **1984**, *17*, 289–296.
- (51) Wiberg, K. B.; Murcko, M. A. *J. Am. Chem. Soc.* **1988**, *110*, 8029–8038.
- (52) Hung, S.-C.; Lin, C.-C.; Wong, C.-H. *Tetrahedron Lett.* **1997**, *38*, 5419–5422.
- (53) Dondoni, A.; Mariotti, G.; Marra, A. *J. Org. Chem.* **2002**, *67*, 4475–4486.
- (54) Merino, P.; Delso, I.; Tejero, T.; Cardona, F.; Marradi, M.; Faggi, E.; Parmeggiani, C.; Goti, A. *Eur. J. Org. Chem.* **2008**, 2929–2947.
- (55) Revuelta, J.; Cicchi, S.; Brandi, A. *J. Org. Chem.* **2005**, *70*, 5636–5642.
- (56) Yoda, H.; Kawauchi, M.; Takabe, K. *Synlett* **1998**, 137–138.
- (57) Zheng, J.-L.; Liu, H.; Zhang, Y.-F.; Zhao, W.; Tong, J.-S.; Ruan, Y.-P.; Huang, P.-Q. *Tetrahedron: Asymmetry* **2011**, *22*, 257–263.
- (58) Meng, W.-H.; Wu, T.-J.; Zhang, H.-K.; Huang, P.-Q. *Tetrahedron: Asymmetry* **2004**, *15*, 3899–3910.
- (59) Arndt, H.-D.; Polborn, K.; Koert, U. *Tetrahedron Lett.* **1997**, *38*, 3879–3882.
- (60) Zanardi, F.; Sartori, A.; Curti, C.; Battistini, L.; Rassa, G.; Nicastro, G.; Casiraghi, G. *J. Org. Chem.* **2007**, *72*, 1814–1817.
- (61) Arndt, H.-D.; Welz, R.; Müller, S.; Ziemer, B.; Koert, U. *Chem. Eur. J.* **2004**, *10*, 3945–3962.
- (62) Hashimoto, M.; Matsumoto, M.; Terashima, S. *Tetrahedron* **2003**, *59*, 3019–3040.
- (63) Buchwald, S. L.; LaMaire, S. J.; Nielsen, R. B.; Watson, B. T.; King, S. M. *Org. Synth.* **1993**, *71*, 77–78.
- (64) Complete crystallographic data for the structural analysis of **11** have been deposited with the Cambridge Data Center: CCDC 1018664.